ofloxacin has been researched along with Urinary Tract Infections in 235 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Urinary Tract Infections: Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prulifloxacin is as effective and well tolerated as levofloxacin in the treatment of respiratory and urinary tract infections." | 9.16 | Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial. ( Chen, Y; Huang, W; Li, Q; Lu, G; Lv, X; Sun, Y; Wu, G; Wu, X; Wu, Y; Yang, H; Zhang, G, 2012) |
| "The aim of this study was to investigate the urinary bactericidal titers (UBTs) and 24-h area under the UBT-versus-time curve (AUBT) of intravenous doripenem (500 mg every 8 h [q8h]), a new carbapenem, versus those of intravenous levofloxacin (250 mg q24h) in patients with complicated urinary tract infections (cUTIs) or pyelonephritis." | 9.14 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ( Naber, KG; Redman, R; Wagenlehner, C; Wagenlehner, FM; Weidner, W, 2009) |
| "Doripenem was evaluated in adults with complicated urinary tract infections and pyelonephritis in two phase 3 studies." | 9.14 | Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis. ( Damiao, R; Davies, T; Kaniga, K; Kotey, P; Naber, KG; Redman, R, 2010) |
| "A clinical study was conducted to compare the efficacy and safety of levofloxacin 750 mg once daily for 5 days to ciprofloxacin twice daily for 10 days for the treatment of complicated urinary tract infections (cUTI) or acute pyelonephritis (AP)." | 9.13 | A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. ( Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Peterson, J, 2008) |
| " This multicenter clinical study was designed to compare FRPM 300 mg 3 times daily to Levofloxacin (LVFX), which is the standard treatment for patients with UTI, 100 mg 3 times daily for 7 days in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy." | 9.10 | [Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy]. ( Fujimoto, N; Iihara, K; Inatomi, H; Kobayashi, T; Matsumoto, T; Muratani, T; Nishimura, T; Takahashi, K; Yamada, Y, 2002) |
| "The objective of this open-label, single-arm, multicenter study was to assess the efficacy and safety of levofloxacin in the treatment of complicated urinary tract infections." | 9.10 | [Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections]. ( Marchetti, F; Trinchieri, A, 2003) |
| "Forty two paraplegic and quadriplegic hospitalized spinal cord injured patients with urinary tract infections (UTI) were included in a double blind, randomized treatment study comparing 7 days ofloxacin (300 mg bd) with trimethoprim-sulphamethoxazole (TMPSMX; 160-800 mg bd) or an alternative, chosen because of resistance to TMPSMX." | 9.09 | Ofloxacin for the treatment of urinary tract infections and biofilms in spinal cord injury. ( Delaney, G; Hayes, K; Hsieh, J; Nicosia, S; Potter, P; Reid, G, 2000) |
| "Levofloxacin, the optical S-(-) isomer of ofloxacin, was compared with ofloxacin in the treatment of complicated urinary tract infections (UTIs)." | 9.09 | Randomized, double-blind, comparative study of levofloxacin and ofloxacin in the treatment of complicated urinary tract infections. ( Peng, MY, 1999) |
| "This double-blind randomized study compared 3-day regimens of cefixime (400 mg once daily) and ofloxacin (200 mg twice a day) in the treatment of urinary tract infections in women." | 9.07 | Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women. ( Leshem, Y; Raz, R; Rottensterich, E; Tabenkin, H, 1994) |
| "In order to reduce the dosage of aminoglycoside in the treatment of patients with complicated urinary tract infections (UTI) in outpatient clinics and to improve cost benefits, we tried both ofloxacin (OFX) treatment and a combination treatment with OFX and a single dose of aminoglycoside (isepamicin)." | 9.07 | Treatment of complicated urinary tract infections with ofloxacin following an aminoglycoside. ( Eto, K; Ishii, T; Kumazawa, J; Matsumoto, T; Saito, Y; Sawae, Y; Ueda, S; Yushita, Y, 1991) |
| "Studies of ofloxacin pharmacokinetics and pathogen susceptibilities suggested that this new fluoroquinolone might be particularly well suited to the treatment of urinary tract infections and prostatitis." | 9.06 | Ofloxacin in the management of complicated urinary tract infections, including prostatitis. ( Cox, CE, 1989) |
| "A single dose of 100 mg ofloxacin was compared with a multiple dose of cotrimoxazole in lower urinary tract infections in 137 women." | 9.06 | Failure of a single dose of 100 mg ofloxacin in lower urinary tract infections in females. ( Forsgren, A; Ode, B; Walder, M, 1987) |
| "The efficacies of ofloxacin and norfloxacin in the treatment of chronic complicated urinary tract infections were compared." | 9.06 | Open randomised comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections. ( Rugendorff, EW, 1987) |
| "A simple open randomized study was performed to evaluate the comparative efficacy and safety of ofloxacin and cotrimoxazole in 40 patients with complicated urinary tract infections." | 9.06 | Ofloxacin vs. cotrimoxazole in patients with complicated urinary tract infections. ( Battaglia, AM; Battaglia, P; Bernardini, G; Vellucci, A, 1987) |
| "A multicenter trial on the efficacy and tolerability of ofloxacin in upper and lower respiratory tract infections and urinary tract infections was carried out on 1,436 patients (926 males and 510 females; mean age 55." | 9.06 | A multicenter study on clinical efficacy of ofloxacin in respiratory and urinary tract infections. ( Grassi, GG, 1986) |
| "Ofloxacin was administered to 18 patients and ciprofloxacin to 17 patients suffering from acute or chronic complicated urinary tract infections." | 9.06 | Clinical evaluation of ofloxacin versus ciprofloxacin in complicated urinary tract infections. ( Kromann-Andersen, B; Larsen, V; Pers, C; Rasmussen, F; Sommer, P, 1986) |
| "The clinical efficacy, safety and usefulness of DL-8280 for the treatment of complicated urinary tract infections were compared with those of pipemidic acid (PPA) by a double-blind method." | 9.05 | [Comparative studies of DL-8280 and pipemidic acid in complicated urinary tract infections by double-blind method]. ( Deguchi, K; Fujita, Y; Kishi, H; Niijima, T; Nishimura, Y; Nito, H; Ogawa, N; Ohmori, H; Saito, I; Tanaka, H, 1984) |
| "ofloxacin has established efficacy in the treatment of a wide variety of urinary tract infections, although, like other fluoroquinolones, it should be used rationally to preserve its activity." | 8.80 | Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. ( Balfour, JA; Lamb, HM; Onrust, SV, 1998) |
| "We evaluated, by Monte Carlo simulation, 500-mg once-daily, 100-mg thrice-daily, 200-mg twice-daily, and 200-mg thrice-daily dose regimens of levofloxacin (LVFX), for the ratio of area under the concentration-time curve for 24 h (AUC(0-24)) to minimum inhibitory concentration (MIC) (AUC(0-24)/MIC) and the ratio of maximum plasma concentration (C(max)) to MIC (C(max)/MIC), which predict microbiological outcomes, and the C(max)/MIC, which inhibits fluoroquinolone resistance selection, in complicated urinary tract infections (UTIs) with Escherichia coli or Pseudomonas aeruginosa." | 7.77 | Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa. ( Deguchi, T; Matsumoto, T; Seike, K; Yasuda, M, 2011) |
| "The pharmacodynamic targets representing 90% probability thresholds for bacterial eradication were determined in patients with complicated urinary tract infections (UTIs) treated with 500mg of levofloxacin every 24h for 7-14 days." | 7.76 | Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ( Arakawa, S; Deguchi, T; Matsumoto, T; Monden, K; Nakane, K; Shimizu, T; Yasuda, M, 2010) |
| "Minimum inhibitory concentrations (MICs) and mutant prevention concentrations (MPCs) of prulifloxacin against 30 strains of Escherichia coli isolated from urinary tract infections as well as the 'biological cost' related to acquisition of resistance to the same drug in 10 uropathogenic E." | 7.74 | In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. ( Gualco, L; Marchese, A; Schito, AM; Schito, GC, 2007) |
| "The aim of this study was to evaluate the in vitro activity of levofloxacin (LVX) in comparison to nalidixic acid (NAL), ofloxacin (OFX), norfloxacin (NOR), amoxicillin (AMX), cefixime (CFM), cotrimoxazole (SXT) and nitrofurantoin (FT), against 402 strains recently isolated from urine specimens in outpatient women suffering from lower urinary tract infections for which short-term treatment was not indicated." | 7.73 | [Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community]. ( Dib, C; Durand, C; Moniot-Ville, N; Weber, P, 2005) |
| "Twenty patients with urinary tuberculosis were treated with ofloxacin (200 mg/day, 6 months), rifampin (600 mg/day, 3 months) and isoniazid (300 mg/day, 3 months) between 1989 and 1990." | 7.71 | Bacteriological conversion in twenty urinary tuberculosis patients treated with ofloxacin, rifampin and isoniazid: a 10-year follow-up study. ( Castiñeiras, AA; Della-Latta, P; Herreras, A; Pérez-Pascual, P; Zarranz, JE, 2002) |
| "The clinical efficacy of a single-day oral administration of levofloxacin (LVFX) for the prevention of urinary tract infections (UTI) after urogenital examinations and treatments for outpatients was assessed." | 7.71 | [Efficacy of a single-day administration of levofloxacin for the prevention of urinary tract infections after urogenital examinations and treatments for outpatients]. ( Arai, G; Hayashi, T; Hyochi, N; Kageyama, Y; Kawakami, S; Kihara, K; Kobayashi, T; Masuda, H; Okuno, T; Saito, K; Sakai, Y; Suzuki, M, 2001) |
| "Minimum inhibitory concentrations (MICs) of gatifloxacin were compared with those of gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin using an agar dilution method for 400 uropathogens cultured from the urine of urological patients with complicated and/or hospital-acquired urinary tract infections (UTI)." | 7.70 | In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections. ( Hollauer, K; Kirchbauer, D; Naber, KG; Witte, W, 2000) |
| "The minimal inhibitory concentrations (MIC) of ofloxacin against 400 isolates cultured from the urine of urological patients with complicated urinary tract infections (UTI) resulted in an inhibition of 94% (99%) of the gram-negative strains at a concentration of 1 mg/l (2 mg/l) and an inhibition of 59% (100%) of the gram-positive strains at a concentration of 1 mg/l (4 mg/l)." | 7.67 | [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections]. ( Adam, D; Bartosik-Wich, B; Naber, KG; Wittenberger, R, 1986) |
| "The clinical efficacy of the new quinolone antibacterial agent ofloxacin (OFLX) on urinary tract infections (UTI) was reevaluated." | 7.67 | [Clinical reevaluation of ofloxacin (OFLX) in urinary tract infections]. ( Akiyama, T; Kurita, T; Matsuura, T, 1988) |
| "To study the treatment effects of ofloxacin (OFLX) on the patients with complicated urinary tract infections (UTI), OFLX at a daily dose of 600 mg divided into either two or three doses per day, was administered for 14 days to 114 patients with complicated UTI." | 7.67 | [Treatment of complicated urinary tract infections by ofloxacin]. ( Horiuchi, S; Kaneoya, F; Kojima, S; Nakame, Y; Negishi, T; Saitoh, H; Satake, I; Takahashi, T; Tari, K; Yoshida, K, 1988) |
| "In this study the in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections was examined." | 7.67 | [The in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections]. ( Tunçkanat, F; Yuluğ, N, 1988) |
| "During 1984 to 1988, 35 patients with urinary tract infection (UTI) and 37 patients with enteric fever were treated successfully with 400 mg ofloxacin twice a day for 7 to 10 days." | 7.67 | In vitro and clinical evaluation of ofloxacin in urinary tract infection and enteric fever. ( Srimuang, S; Tanphaichitra, D, 1988) |
| "Fifty-three patients with urinary tract infections (UTI) were treated with Ofloxacin, a new oral synthetic antimicrobial agent, and its clinical efficacy was studied." | 7.67 | [Clinical study of ofloxacin (OFLX) on urinary tract infections]. ( Inada, F; Inagaki, N; Miyata, M; Mizunaga, M; Morikawa, M; Okamura, K; Osanai, H; Yachiku, S, 1987) |
| "Clinical efficacy of ofloxacin (OFLX) against complicated urinary tract infections was examined in 20 patients." | 7.67 | [Clinical evaluation of ofloxacin against complicated urinary tract infections]. ( Nishio, S; Yoshihara, H, 1987) |
| "Doripenem was found not to be inferior to levofloxacin in terms of therapeutics and is now approved for use in the United States and Europe for the treatment of adults with cUTI, including pyelonephritis." | 6.74 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. ( Hedrich, D; Kaniga, K; Kotey, P; Llorens, L; Naber, KG; Redman, R, 2009) |
| " This study concluded that the dosage regimen of LVFX 500 mg once daily was effective and tolerable for the treatment of LRTIs and UTIs." | 6.74 | Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. ( Chen, BY; Ding, GH; Duan, J; Gu, JM; Guo, DY; Hao, QL; Huang, HH; Huang, JA; Li, HY; Li, QH; Liu, A; Lü, XJ; Ma, H; Ren, ZY; Shen, HH; Shi, MH; Si, B; Sun, SH; Sun, TY; Wu, GM; Xia, QM; Xiao, W; Xiao, ZK; Xiu, QY; Yang, HF; Yang, HP; Yao, WZ; Ying, KJ; Yu, YS; Yue, HM; Zhang, W; Zhang, YY; Zheng, HG, 2009) |
| "The study shows that it is possible to treat complicated urinary tract infections just as successfully with 200 mg i." | 6.67 | Comparison of i.v. ofloxacin and piperacillin in the treatment of complicated urinary tract infections. ( Schalkhäuser, K, 1990) |
| "Levofloxacin is a second generation fluoroquinolone with a post marketing history of well tolerated and successful use in a variety of clinical situations." | 6.41 | A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. ( Garvin, CG; Jung, R; Martin, SJ, 2001) |
| "Levofloxacin was given to each patient at a dose of 300 mg or 400 mg a day for 7-14 days (average 12." | 5.28 | [Clinical study of levofloxacin (DR-3355) on uro-genital infections--with special reference to usefulness for chronic prostatitis]. ( Horiba, M; Suzuki, K, 1992) |
| "Ofloxacin can cause retarded ossification and arthropathy in young animals, but there is no published information about its teratogenicity in humans." | 5.28 | Ofloxacin during the second trimester of pregnancy. ( Friedman, S; Hod, M; Merlob, P; Peled, Y, 1991) |
| "An analysis of subjects with concurrent bacteraemia and either nosocomial pneumonia, complicated intra-abdominal infection or complicated urinary tract infection from six phase 3 clinical trials demonstrated similar cure rates and clearance of bacteraemia in patients treated with doripenem and comparator agents." | 5.17 | Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials. ( Kaniga, K; Lee, M; Redman, R; Rice, DA, 2013) |
| "Prulifloxacin is as effective and well tolerated as levofloxacin in the treatment of respiratory and urinary tract infections." | 5.16 | Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial. ( Chen, Y; Huang, W; Li, Q; Lu, G; Lv, X; Sun, Y; Wu, G; Wu, X; Wu, Y; Yang, H; Zhang, G, 2012) |
| "The aim of this study was to investigate the urinary bactericidal titers (UBTs) and 24-h area under the UBT-versus-time curve (AUBT) of intravenous doripenem (500 mg every 8 h [q8h]), a new carbapenem, versus those of intravenous levofloxacin (250 mg q24h) in patients with complicated urinary tract infections (cUTIs) or pyelonephritis." | 5.14 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ( Naber, KG; Redman, R; Wagenlehner, C; Wagenlehner, FM; Weidner, W, 2009) |
| "Doripenem was evaluated in adults with complicated urinary tract infections and pyelonephritis in two phase 3 studies." | 5.14 | Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis. ( Damiao, R; Davies, T; Kaniga, K; Kotey, P; Naber, KG; Redman, R, 2010) |
| "A clinical study was conducted to compare the efficacy and safety of levofloxacin 750 mg once daily for 5 days to ciprofloxacin twice daily for 10 days for the treatment of complicated urinary tract infections (cUTI) or acute pyelonephritis (AP)." | 5.13 | A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. ( Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Peterson, J, 2008) |
| "The objective of this multicenter, randomized, controlled, parallel group trial was to evaluate the efficacy of levofloxacin 250 mg oral, once daily (LVFX), placebo one tablet oral once daily (Placebo [P] group) and ciprofloxacin (CPFX) 500 mg oral, twice daily (single blind), prophylaxis in preventing bacteriuria (> or = 10(3) CFU/ml) in post-surgical catheterized patients." | 5.12 | A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones. ( Drago, L; Esposito, S; Leone, S; Marchetti, F; Marvaso, A; Noviello, S, 2006) |
| " Overall bacteriuria rate at day 5 to 7 was 22% (levofloxacin 21%; TMP/SMZ 20%; control group 30%)." | 5.11 | Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate. ( Naber, KG; Schinzel, S; Wagenlehner, C; Wagenlehner, FM, 2005) |
| " This multicenter clinical study was designed to compare FRPM 300 mg 3 times daily to Levofloxacin (LVFX), which is the standard treatment for patients with UTI, 100 mg 3 times daily for 7 days in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy." | 5.10 | [Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy]. ( Fujimoto, N; Iihara, K; Inatomi, H; Kobayashi, T; Matsumoto, T; Muratani, T; Nishimura, T; Takahashi, K; Yamada, Y, 2002) |
| "The objective of this open-label, single-arm, multicenter study was to assess the efficacy and safety of levofloxacin in the treatment of complicated urinary tract infections." | 5.10 | [Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections]. ( Marchetti, F; Trinchieri, A, 2003) |
| "Forty two paraplegic and quadriplegic hospitalized spinal cord injured patients with urinary tract infections (UTI) were included in a double blind, randomized treatment study comparing 7 days ofloxacin (300 mg bd) with trimethoprim-sulphamethoxazole (TMPSMX; 160-800 mg bd) or an alternative, chosen because of resistance to TMPSMX." | 5.09 | Ofloxacin for the treatment of urinary tract infections and biofilms in spinal cord injury. ( Delaney, G; Hayes, K; Hsieh, J; Nicosia, S; Potter, P; Reid, G, 2000) |
| " They were compared with 23 acute pyelonephritis patients given ciprofloxacin in a dose 1 g/day." | 5.09 | [Tavanik effectiveness and safety in the treatment of urinary tract infection complications]. ( Loran, OB; Pushkar', DIu; Rasner, PI, 2001) |
| "The efficacy and safety of ofloxacin in the treatment of upper and lower urinary tract infections were studied with the drug use according to 4 regimens by comparison with nitrofurantoin in the treatment of lower urinary tract infections and trimethoprim/sulfamethoxazole in the treatment of upper urinary tract infections." | 5.08 | [Clinical experience with the use of ofloxacin in infections of the upper and lower urinary tracts: demonstrations of the results of clinical trials]. ( Liudvig, G, 1996) |
| "The efficacy and safety of levofloxacin and lomefloxacin in complicated urinary tract infections (UTIs) were compared in a randomized, open-label, multicenter study." | 5.08 | A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. ( Callery-D'Amico, S; Cox, CE; Fowler, CL; Kim, SS; King, W; Klimberg, IW, 1998) |
| "The efficacy and safety of a 3-day regimen of sparfloxacin were compared with those of a 3-day regimen of ofloxacin for the treatment of community-acquired acute uncomplicated urinary tract infections." | 5.08 | Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. ( Dorr, MB; Ellison, W; Henry, D; Magner, DJ; Mansfield, DL; Sullivan, J; Talbot, GH, 1998) |
| "This double-blind randomized study compared 3-day regimens of cefixime (400 mg once daily) and ofloxacin (200 mg twice a day) in the treatment of urinary tract infections in women." | 5.07 | Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women. ( Leshem, Y; Raz, R; Rottensterich, E; Tabenkin, H, 1994) |
| "A total of 125 ambulatory women (85 premenopausal and 40 postmenopausal) who experienced 174 acute urinary tract infections with mainly gram-negative bacteria (99%) was randomized to receive a single dose, 2-tablet treatment with either ofloxacin (400 mg." | 5.07 | Single dose quinolone treatment in acute uncomplicated urinary tract infection in women. ( Pfau, A; Sacks, TG, 1993) |
| "The efficacy and safety of ofloxacin for the treatment of pneumonia, urinary infection and skin infections in the institutionalized elderly is being studied in a multicenter North American trial." | 5.07 | Ofloxacin use in a geriatric population. ( Alessi, P; Cullison, J; Degelau, J; Meyers, B; Nicolle, LE, 1991) |
| "In order to reduce the dosage of aminoglycoside in the treatment of patients with complicated urinary tract infections (UTI) in outpatient clinics and to improve cost benefits, we tried both ofloxacin (OFX) treatment and a combination treatment with OFX and a single dose of aminoglycoside (isepamicin)." | 5.07 | Treatment of complicated urinary tract infections with ofloxacin following an aminoglycoside. ( Eto, K; Ishii, T; Kumazawa, J; Matsumoto, T; Saito, Y; Sawae, Y; Ueda, S; Yushita, Y, 1991) |
| "Studies of ofloxacin pharmacokinetics and pathogen susceptibilities suggested that this new fluoroquinolone might be particularly well suited to the treatment of urinary tract infections and prostatitis." | 5.06 | Ofloxacin in the management of complicated urinary tract infections, including prostatitis. ( Cox, CE, 1989) |
| "The drug Ofloxacin was tried clinically on 54 patients with different bacterial infections." | 5.06 | [Clinical trial of ofloxacin (Tarivid R)]. ( Angelova, I; Belovezhdov, N; Talakova, Ch, 1988) |
| "A single dose of 100 mg ofloxacin was compared with a multiple dose of cotrimoxazole in lower urinary tract infections in 137 women." | 5.06 | Failure of a single dose of 100 mg ofloxacin in lower urinary tract infections in females. ( Forsgren, A; Ode, B; Walder, M, 1987) |
| "The efficacies of ofloxacin and norfloxacin in the treatment of chronic complicated urinary tract infections were compared." | 5.06 | Open randomised comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections. ( Rugendorff, EW, 1987) |
| "A simple open randomized study was performed to evaluate the comparative efficacy and safety of ofloxacin and cotrimoxazole in 40 patients with complicated urinary tract infections." | 5.06 | Ofloxacin vs. cotrimoxazole in patients with complicated urinary tract infections. ( Battaglia, AM; Battaglia, P; Bernardini, G; Vellucci, A, 1987) |
| "A multicenter trial on the efficacy and tolerability of ofloxacin in upper and lower respiratory tract infections and urinary tract infections was carried out on 1,436 patients (926 males and 510 females; mean age 55." | 5.06 | A multicenter study on clinical efficacy of ofloxacin in respiratory and urinary tract infections. ( Grassi, GG, 1986) |
| " regarding the safety and efficacy of ofloxacin in the treatment of urinary tract infections are presented." | 5.06 | Clinical experience with ofloxacin in urinary tract infection. ( Callery, SV; Cox, CE; Tack, KJ, 1986) |
| "Ofloxacin was administered to 18 patients and ciprofloxacin to 17 patients suffering from acute or chronic complicated urinary tract infections." | 5.06 | Clinical evaluation of ofloxacin versus ciprofloxacin in complicated urinary tract infections. ( Kromann-Andersen, B; Larsen, V; Pers, C; Rasmussen, F; Sommer, P, 1986) |
| "The clinical efficacy, safety and usefulness of DL-8280 for the treatment of complicated urinary tract infections were compared with those of pipemidic acid (PPA) by a double-blind method." | 5.05 | [Comparative studies of DL-8280 and pipemidic acid in complicated urinary tract infections by double-blind method]. ( Deguchi, K; Fujita, Y; Kishi, H; Niijima, T; Nishimura, Y; Nito, H; Ogawa, N; Ohmori, H; Saito, I; Tanaka, H, 1984) |
| "Levofloxacin and sparfloxacin are active against pathogens frequently involved in community-acquired upper and lower respiratory tract infections, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydia pneumoniae." | 4.80 | Levofloxacin and sparfloxacin: new quinolone antibiotics. ( Chuck, SK; Jung, R; Martin, SJ; Messick, CR; Meyer, JM; Pendland, SL, 1998) |
| "ofloxacin has established efficacy in the treatment of a wide variety of urinary tract infections, although, like other fluoroquinolones, it should be used rationally to preserve its activity." | 4.80 | Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. ( Balfour, JA; Lamb, HM; Onrust, SV, 1998) |
| "We evaluated, by Monte Carlo simulation, 500-mg once-daily, 100-mg thrice-daily, 200-mg twice-daily, and 200-mg thrice-daily dose regimens of levofloxacin (LVFX), for the ratio of area under the concentration-time curve for 24 h (AUC(0-24)) to minimum inhibitory concentration (MIC) (AUC(0-24)/MIC) and the ratio of maximum plasma concentration (C(max)) to MIC (C(max)/MIC), which predict microbiological outcomes, and the C(max)/MIC, which inhibits fluoroquinolone resistance selection, in complicated urinary tract infections (UTIs) with Escherichia coli or Pseudomonas aeruginosa." | 3.77 | Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa. ( Deguchi, T; Matsumoto, T; Seike, K; Yasuda, M, 2011) |
| "We examined Enterococcus faecalis strains clinically isolated from 100 patients with urinary tract infections (UTIs) for their susceptibility to levofloxacin (LVX) by measuring the MIC and investigated amino acid mutations by direct DNA sequencing, which were then correlated with LVX resistance." | 3.77 | Mechanisms of and risk factors for fluoroquinolone resistance in clinical Enterococcus faecalis isolates from patients with urinary tract infections. ( Arakawa, S; Fujisawa, M; Kawabata, M; Matsumoto, M; Nakano, Y; Shigemura, K; Shirakawa, T; Tanaka, K; Yasufuku, T, 2011) |
| "The pharmacodynamic targets representing 90% probability thresholds for bacterial eradication were determined in patients with complicated urinary tract infections (UTIs) treated with 500mg of levofloxacin every 24h for 7-14 days." | 3.76 | Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ( Arakawa, S; Deguchi, T; Matsumoto, T; Monden, K; Nakane, K; Shimizu, T; Yasuda, M, 2010) |
| "Because of high rates of trimethoprim-sulfamethoxazole resistance in Escherichia coli, Denver Health switched to levofloxacin as the initial therapy for urinary tract infections (UTIs) in 1999." | 3.74 | Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. ( Burman, WJ; Everhart, RM; Johnson, L; MacKenzie, TD; Mehler, PS; Price, CS; Rome, M; Rozwadowski, J; Sabel, A, 2008) |
| "Minimum inhibitory concentrations (MICs) and mutant prevention concentrations (MPCs) of prulifloxacin against 30 strains of Escherichia coli isolated from urinary tract infections as well as the 'biological cost' related to acquisition of resistance to the same drug in 10 uropathogenic E." | 3.74 | In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. ( Gualco, L; Marchese, A; Schito, AM; Schito, GC, 2007) |
| "The aim of this study was to evaluate the in vitro activity of levofloxacin (LVX) in comparison to nalidixic acid (NAL), ofloxacin (OFX), norfloxacin (NOR), amoxicillin (AMX), cefixime (CFM), cotrimoxazole (SXT) and nitrofurantoin (FT), against 402 strains recently isolated from urine specimens in outpatient women suffering from lower urinary tract infections for which short-term treatment was not indicated." | 3.73 | [Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community]. ( Dib, C; Durand, C; Moniot-Ville, N; Weber, P, 2005) |
| "Comparative susceptibility of microflora isolates from patients with complicated urinary tract infections to cefepime, other cephalosporins, amikacin, ciprofloxacin and ofloxacin was studied." | 3.72 | [Cefepime (maxipime) in the treatment of severe urinary tract infection]. ( Derevianko, II, 2003) |
| "Twenty patients with urinary tuberculosis were treated with ofloxacin (200 mg/day, 6 months), rifampin (600 mg/day, 3 months) and isoniazid (300 mg/day, 3 months) between 1989 and 1990." | 3.71 | Bacteriological conversion in twenty urinary tuberculosis patients treated with ofloxacin, rifampin and isoniazid: a 10-year follow-up study. ( Castiñeiras, AA; Della-Latta, P; Herreras, A; Pérez-Pascual, P; Zarranz, JE, 2002) |
| "We studied gastrointestinal (GI) colonization by Candida albicans in patients receiving oral norfloxacin, ciprofloxacin or ofloxacin as monotherapy for urinary tract infections." | 3.71 | The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans. ( Cranidis, A; Kontoyiannis, DP; Maraki, S; Mavromanolakis, E; Samonis, G; Tselentis, Y, 2001) |
| "When seven elderly patients with fever due to bacterial infection failed to respond to ofloxacin 300 mg/day for 3 days, we prescribed Mao-bushi-saishin-to for 7 days." | 3.70 | Effect of Mao-bushi-saishin-to on infection of ofloxacin resistant bacteria and of unknown origin. ( Kamei, T; Tomioka, H; Toriumi, Y, 2000) |
| "The efficacy of single dose ofloxacin in lower urinary tract infections was investigated in this study." | 3.68 | Single dose of ofloxacin treatment in women with dysuria and frequency. ( Akdaş, A; Dillioğlugil, O; Ilker, Y; Simşek, F, 1993) |
| "The effects of orally administered ofloxacin on functional parameters of cell-mediated immunity were investigated in 15 patients with respiratory or urinary tract infections." | 3.68 | Effects of ofloxacin on cell-mediated immune response and lymphokine production. ( Arpinelli, F; Benedetti, M; Biglino, A; Busso, M; Forno, B; Pollono, AM; Pugliese, A, 1990) |
| "The minimal inhibitory concentrations (MIC) of ofloxacin against 400 isolates cultured from the urine of urological patients with complicated urinary tract infections (UTI) resulted in an inhibition of 94% (99%) of the gram-negative strains at a concentration of 1 mg/l (2 mg/l) and an inhibition of 59% (100%) of the gram-positive strains at a concentration of 1 mg/l (4 mg/l)." | 3.67 | [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections]. ( Adam, D; Bartosik-Wich, B; Naber, KG; Wittenberger, R, 1986) |
| " Among quinolones, the most active agents are ciprofloxacin and ofloxacin (MIC modes: 4 and 2 mg/l), so these antimicrobials could be used for the treatment of urinary tract infections caused by Corynebacterium group D2." | 3.67 | [Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity]. ( Cancet, B; Clave, D; Didier, J; Henry-Ferry, S; Marty, N, 1988) |
| "The therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 was compared in alloxan-induced diabetic mice with experimental respiratory and urinary tract infections." | 3.67 | Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice. ( Nishino, T; Obana, Y, 1988) |
| "During 1984 to 1988, 35 patients with urinary tract infection (UTI) and 37 patients with enteric fever were treated successfully with 400 mg ofloxacin twice a day for 7 to 10 days." | 3.67 | In vitro and clinical evaluation of ofloxacin in urinary tract infection and enteric fever. ( Srimuang, S; Tanphaichitra, D, 1988) |
| " It was used alone 26 times and on 6 occasions it was associated with rifampin on 6 staphylococcal infections." | 3.67 | [Ofloxacin (RU 43280). Clinical study]. ( Bertrand, A; Despaux, E; Janbon, F; Jonquet, O; Reynes, J, 1987) |
| "Fifty-three patients with urinary tract infections (UTI) were treated with Ofloxacin, a new oral synthetic antimicrobial agent, and its clinical efficacy was studied." | 3.67 | [Clinical study of ofloxacin (OFLX) on urinary tract infections]. ( Inada, F; Inagaki, N; Miyata, M; Mizunaga, M; Morikawa, M; Okamura, K; Osanai, H; Yachiku, S, 1987) |
| "Ofloxacin, a new fluoroquinolone, was given to fifty patients (29 females and 21 males) aged 25 to 86 years with urinary tract infection or prostatitis." | 3.67 | [Ofloxacin (RU 43280): clinical evaluation in urinary and prostatic infections]. ( Acar, JF; Guibert, J, 1986) |
| "A treatment with ofloxacin for 7 days was inferior to 14 days for febrile UTI in men and should therefore not be recommended." | 3.30 | Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial. ( Abgrall, S; Aparicio, C; Aumaitre, H; Bercot, B; Bernard, L; Bourgarit-Durand, A; Bruyere, F; Canoui, E; Chabrol, A; Charlier, C; Chevret, S; de Lastours, V; Desseaux, K; Empana-Barat, F; Escaut, L; Etienne, M; Ferreyra, M; Fontaine, JP; Garrait, V; Gatey, C; Grall, N; Jaureguiberry, S; Lafaurie, M; Lefort, A; Madeleine, I; Meyssonnier, V; Molina, JM; Mongiat-Artus, P; Morrier, M; Pacanowski, J; Piet, E; Talarmin, JP, 2023) |
| "Doripenem was found not to be inferior to levofloxacin in terms of therapeutics and is now approved for use in the United States and Europe for the treatment of adults with cUTI, including pyelonephritis." | 2.74 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. ( Hedrich, D; Kaniga, K; Kotey, P; Llorens, L; Naber, KG; Redman, R, 2009) |
| " This study concluded that the dosage regimen of LVFX 500 mg once daily was effective and tolerable for the treatment of LRTIs and UTIs." | 2.74 | Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. ( Chen, BY; Ding, GH; Duan, J; Gu, JM; Guo, DY; Hao, QL; Huang, HH; Huang, JA; Li, HY; Li, QH; Liu, A; Lü, XJ; Ma, H; Ren, ZY; Shen, HH; Shi, MH; Si, B; Sun, SH; Sun, TY; Wu, GM; Xia, QM; Xiao, W; Xiao, ZK; Xiu, QY; Yang, HF; Yang, HP; Yao, WZ; Ying, KJ; Yu, YS; Yue, HM; Zhang, W; Zhang, YY; Zheng, HG, 2009) |
| "Prostate cancer was present in 93 patients (23%)." | 2.70 | Single dose levofloxacin prophylaxis for prostate biopsy in patients at low risk. ( Ali-Khan, MM; Canby-Hagino, E; Foley, JP; Griffith, BC; Morey, AF; Rozanski, TA, 2002) |
| " This pharmacokinetic modeling could be used to determine optimal treatment dose in clinical trials in a shorter time frame with fewer patients." | 2.69 | Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. ( Berman, AL; Chow, AT; Corrado, M; Dornseif, B; Drusano, GL; Fowler, CL; Natarajan, J; Preston, SL; Reichl, V, 1998) |
| "Ofloxacin was well tolerated: adverse events were reported by 67 (12." | 2.67 | Ofloxacin versus trimethoprim and co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. ( Cole, TP; Spencer, RC, 1992) |
| "The present study was undertaken to evaluate the clinical efficacy of long-term administration of ofloxacin (OFLX) to the patients following transurethral resection of the prostate." | 2.67 | [Study of the long-term administration of ofloxacin to the patients following transurethral resection of the prostate]. ( Hasuda, A; Morita, M; Suzuki, K, 1991) |
| " A treatment course of ofloxacin, once-a-day for three days, was as safe and effective as a standard course of TMP/SMX, twice a day for seven days." | 2.67 | Randomized study to evaluate efficacy and safety of ofloxacin vs. trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection. ( Basista, MP, 1991) |
| "Ofloxacin was administered orally at a daily dosage of 300 mg and 600 mg in three divided doses for 14 days to 24 and 60 patients with chronic complicated urinary infections, respectively, in order to evaluate the therapeutic efficacy." | 2.67 | [Clinical evaluation of ofloxacin in the treatment of chronic complicated urinary tract infection]. ( Hisazumi, H; Kobashi, K; Koizumi, H; Motoi, I; Nagano, K; Nishino, A; Orito, M; Sawaki, M; Shyoda, R; Uchibayashi, T, 1990) |
| "Ofloxacin treatment was used for the treatment of lower respiratory tract infections in 35 patients." | 2.67 | Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study. ( Regamey, C; Steinbach-Lebbin, C, 1990) |
| " Dosage adjustment was made for patients in renal failure." | 2.67 | Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients. ( Beaucaire, G; Beuscart, C; Chidiac, C; Leroy, O; Mouton, Y; Senneville, E; Sivery, B; Vincent du Laurier, M, 1990) |
| "The study shows that it is possible to treat complicated urinary tract infections just as successfully with 200 mg i." | 2.67 | Comparison of i.v. ofloxacin and piperacillin in the treatment of complicated urinary tract infections. ( Schalkhäuser, K, 1990) |
| "Ofloxacin was administered in three different dosages in order to evaluate drug efficacy and tolerance: 600 mg/day for 3 days in 22 cases; 300 mg/day for 3 days in 22 cases; 600 mg/day for 5 days in 1 case." | 2.66 | [Use of ofloxacin in 45 cases of infection of the lower urinary tract in women]. ( Bottino, G; Marinello, M; Menna, C; Vergano, RM, 1989) |
| "Ofloxacin was also effective in the treatment of enteric fever, in which eradication was achieved in all seven patients." | 2.66 | Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections. ( Sahaphong, S; Srimuang, S; Tanphaichitra, D, 1986) |
| "Ofloxacin is a new quinolone-carboxylic acid derivative with a broad spectrum of activity, excellent bioavailability after oral administration and insignificant metabolisation." | 2.66 | [Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe]. ( Blomer, R; Bruch, K; Zahlten, RN, 1986) |
| "Renal parenchymal malacoplakia is a rare cause of acute renal failure." | 2.42 | Renal parenchymal malacoplakia: a rare cause of ARF with a review of recent literature. ( Chan, KW; Kung, WH; Li, R; Tam, VK, 2003) |
| " Many of the fluoroquinolone agents have once-daily dosing regimens, enhancing patient adherence." | 2.41 | The expanding role of fluoroquinolones. ( Schaeffer, AJ, 2002) |
| "Levofloxacin is a second generation fluoroquinolone with a post marketing history of well tolerated and successful use in a variety of clinical situations." | 2.41 | A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. ( Garvin, CG; Jung, R; Martin, SJ, 2001) |
| "Oral levofloxacin was also similar in efficacy to amoxicillin/clavulanic acid or oral clarithromycin in patients with acute maxillary sinusitis treated for 7 to 14 days." | 2.40 | Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. ( Lamb, HM; Langtry, HD, 1998) |
| "Ofloxacin is a quinolone carboxylic acid with a broad spectrum of activity for gram-negative pathogens that are common causes of urologic infections including cystitis, pyelonephritis, and prostatitis." | 2.38 | Worldwide clinical experience with ofloxacin in urologic cases. ( Corrado, ML, 1991) |
| "G6PD deficiency is very frequent with almost 400 millions of patients worldwide in Asia, Africa and Mediterranean." | 1.35 | [Ofloxacin is contraindicated in case of G6PD deficiency: is it evidenced based?]. ( Algayres, JP; Bonnefoy, S; Bordier, L; Callot, D; Carmoi, T; Lecoules, S, 2009) |
| "Levofloxacin 500 mg was given to 24 of the 85 patients who underwent simultaneous hysterectomy by intravenous injection since 1 day after the operation once a day and then given orally once a day for 4-8 days when the condition was improved." | 1.35 | [Prevention of peri-operative infection with levofloxacin in female patients undergoing surgery for stress urinary incontinence]. ( Cao, DY; Wang, JH; Zhang, Y; Zhu, L, 2008) |
| "Bacterial prostatitis is documented at a very low prevalence (7-13% of prostatitis overall considered) due to either reduced utilization of viral and bacteriological tests (Meares test, urethral swab, bacterial and viral PCR) or to the possibility that individual patients show a scarce expression of bacterial disease in biological fluids, because of intraglandular biofilm presence, with subsequent spreading of the sole plankton microrganisms." | 1.35 | [Chronic prostatitis and biofilm]. ( Bartoletti, R; Cai, T, 2009) |
| "aeruginosa from respiratory tract infections at 13-21%, which was the same trend as in past years." | 1.35 | [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007]. ( Aihara, M; Akiyama, T; Akizawa, K; Aoki, Y; Asano, Y; Baba, H; fujimoto, Y; Fujita, J; Fujita, S; Fujiwara, H; Genma, H; Gonda, H; Haruki, K; Hashikita, G; Hayashi, M; Heijyou, H; Hida, Y; Hiramatsu, K; Horiuchi, H; Ichiyama, S; Idomuki, M; Ieiri, T; Ikeda, N; Inuzuka, K; Iriyama, J; Ishii, Y; Ito, T; Iwata, M; Kaku, M; Kamioka, M; Kanda, M; Kang, D; Kanno, H; Katayama, Y; Kato, J; Kawahara, K; Kawamura, C; Kawano, S; Kawashima, C; Kinoshita, S; Kobayashi, Y; Kohno, S; Koike, K; Kon, S; Kondou, S; Kono, H; Kumasaka, K; Kusaba, K; Kusakabe, T; Kusano, N; Kuwabara, M; Maekawa, M; Maesaki, S; Masaki, H; Mashiba, K; Matsuda, J; Matsuda, K; Matsuo, S; Miki, M; Misawa, S; Miyajima, E; Miyanohara, H; Moro, K; Murakami, M; Murase, M; Murata, M; Nagai, A; Nakagawa, T; Nakamura, K; Nakashima, Y; Nakasone, I; Nakatani, K; Nakaya, H; Negayama, K; Ohno, A; Oka, M; Okabe, H; Okada, M; Okamoto, H; Okamoto, Y; Okayama, A; Okazaki, T; Okubo, S; Ono, J; Ota, H; Ozaki, Y; Saikawa, T; Saito, T; Sano, R; Sekine, I; Shigeta, M; Shimizu, C; Shiotani, J; Soma, M; Sugita, A; Sugiura, T; Sumitomo, M; Suwabe, A; Takubo, T; Taniguchi, N; Tashiro, H; Tateda, K; Tazawa, Y; Tominaga, M; Toyoshima, S; Uchida, T; Yamaguchi, I; Yamaguchi, K; Yamahata, K; Yamamoto, G; Yamamoto, Y; Yamane, N; Yamashita, M; Yamazaki, K; Yanagihara, K; Yasujima, M; Yoneyama, A; Yoshida, H; Yoshimura, H; Yuzuki, Y, 2009) |
| " By the antibacterial activity and bioavailability sodium furasidin is advantages among the nitrofurans." | 1.33 | [Results of the study on antibiotic resistance emergence among pathogens of community-acquired urinary tract infections in Moscow. Phase I]. ( Ivanov, DV; Sidorenko, SV, 2005) |
| " pneumoniae, MPC results were below susceptible breakpoints and within clinically achievable and sustainable drug concentrations for >24 hours of the dosing interval against." | 1.33 | Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. ( Blondeau, JM; Hansen, GT, 2005) |
| "Polymorphic ventricular tachycardia (PVT) is a form of ventricular tachycardia characterized by QRS complexes that seem to change direction during the tachycardia." | 1.31 | Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. ( Mousavi, MS; O'Donoghue, S; Paltoo, B, 2001) |
| "Ten patients with clinical symptoms of benign prostatic hyperplasia undergoing TUR-P received 200 mg of both drugs per os simultaneously 2 hours before surgery." | 1.31 | Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate. ( Chen, J; Chen, RR; Huang, HS, 2001) |
| "Ofloxacin serum levels were analyzed once prior to, on day 6 during and on day 3 after drug administration." | 1.30 | The influence of ofloxacin (Tarivid) on the parasite-host inter-relationship in patients with chronic urinary tract infection. ( Fünfstück, R; Gerth, J; Schubert, K; Stein, G; Straube, E; Wolfram, M, 1999) |
| "Levofloxacin was given to each patient at a dose of 300 mg or 400 mg a day for 7-14 days (average 12." | 1.28 | [Clinical study of levofloxacin (DR-3355) on uro-genital infections--with special reference to usefulness for chronic prostatitis]. ( Horiba, M; Suzuki, K, 1992) |
| "Ofloxacin was determined to have the widest spectrum of activity and potential empiric use (90." | 1.28 | Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group. ( Erwin, ME; Jones, RN; Reller, LB; Rosati, LA; Sanchez, ML, 1992) |
| "Against respiratory tract infections with K." | 1.28 | In vivo evaluation of NM441, a new thiazeto-quinoline derivative. ( Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y, 1991) |
| "Ofloxacin can cause retarded ossification and arthropathy in young animals, but there is no published information about its teratogenicity in humans." | 1.28 | Ofloxacin during the second trimester of pregnancy. ( Friedman, S; Hod, M; Merlob, P; Peled, Y, 1991) |
| "Ofloxacin was administered to 26 males infected with Ureaplasma urealyticum." | 1.28 | Effect of ofloxacin in the treatment of genitourinary tract infection with Ureaplasma urealyticum. ( Hoshino, H; Kawamura, N; Koinuma, A; Nakajima, N; Tanaka, M, 1989) |
| "Ofloxacin (Tarivid) is a 4-quinolone of the latest generation." | 1.27 | [Assessment of the genotoxic risk caused by the gyrase inhibitor ofloxacin using sister chromatid exchange rate analysis]. ( Brugger, P; Klein, G; Kullich, W, 1988) |
| "Ofloxacin (OFLX) was administered at a dose of 200 mg, three times daily (600 mg) for 14 days, to 15 patients suffering from complicated urinary tract infection." | 1.27 | [Clinical study of ofloxacin in complicated urinary tract infection]. ( Akazawa, N; Asahi, T; Hayata, S; Okita, K; Sasaki, H; Tsugawa, M, 1988) |
| "Ciprofloxacin was the most active agent." | 1.27 | In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species. ( Allocati, N; Cellini, L; Di Girolamo, A; Piccolomini, R; Scazzocchio, F; Selan, L, 1988) |
| "Treatment with ofloxacin in 15 patients with chronic renal failure at different stages is reported with respect to patients undergoing hemodialysis treatment." | 1.27 | [Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results]. ( Dörfler, A; Schulz, W, 1986) |
| "Ofloxacin was active against all but one (Pseudomonas aeruginosa) blood culture isolates." | 1.27 | Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. ( Alkan, M; Berger, S; Bogokowski, B; Keren, G; Mark, Z; Rubinstein, E, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 57 (24.26) | 18.7374 |
| 1990's | 66 (28.09) | 18.2507 |
| 2000's | 87 (37.02) | 29.6817 |
| 2010's | 21 (8.94) | 24.3611 |
| 2020's | 4 (1.70) | 2.80 |
| Authors | Studies |
|---|---|
| Higashide, M | 1 |
| Kuroda, M | 1 |
| Omura, CT | 1 |
| Kumano, M | 1 |
| Ohkawa, S | 1 |
| Ichimura, S | 1 |
| Ohta, T | 1 |
| Blango, MG | 1 |
| Mulvey, MA | 1 |
| Prasada Rao, CMM | 1 |
| Vennila, T | 1 |
| Kosanam, S | 1 |
| Ponsudha, P | 1 |
| Suriyakrishnaan, K | 1 |
| Alarfaj, AA | 1 |
| Hirad, AH | 1 |
| Sundaram, SR | 1 |
| Surendhar, PA | 1 |
| Selvam, N | 1 |
| Lecuru, M | 1 |
| Daniau, C | 1 |
| Alfandari, S | 1 |
| Dumartin, C | 1 |
| Bajolet, O | 1 |
| Blanchard, H | 1 |
| Simon, L | 1 |
| Colomb-Cotinat, M | 1 |
| Lafaurie, M | 1 |
| Chevret, S | 1 |
| Fontaine, JP | 1 |
| Mongiat-Artus, P | 1 |
| de Lastours, V | 1 |
| Escaut, L | 1 |
| Jaureguiberry, S | 1 |
| Bernard, L | 1 |
| Bruyere, F | 1 |
| Gatey, C | 1 |
| Abgrall, S | 1 |
| Ferreyra, M | 1 |
| Aumaitre, H | 1 |
| Aparicio, C | 1 |
| Garrait, V | 1 |
| Meyssonnier, V | 1 |
| Bourgarit-Durand, A | 1 |
| Chabrol, A | 1 |
| Piet, E | 1 |
| Talarmin, JP | 1 |
| Morrier, M | 1 |
| Canoui, E | 1 |
| Charlier, C | 1 |
| Etienne, M | 1 |
| Pacanowski, J | 1 |
| Grall, N | 1 |
| Desseaux, K | 1 |
| Empana-Barat, F | 1 |
| Madeleine, I | 1 |
| Bercot, B | 1 |
| Molina, JM | 1 |
| Lefort, A | 1 |
| Axford, SB | 1 |
| Andersen, CC | 1 |
| Stark, MJ | 1 |
| Ouni, B | 1 |
| Fathallah, N | 1 |
| Slim, R | 1 |
| Brahim, A | 1 |
| Ben Salem, C | 1 |
| Páez-Canro, C | 1 |
| Alzate, JP | 1 |
| González, LM | 1 |
| Rubio-Romero, JA | 1 |
| Lethaby, A | 1 |
| Gaitán, HG | 1 |
| Rice, DA | 1 |
| Kaniga, K | 3 |
| Lee, M | 1 |
| Redman, R | 4 |
| Goyal, T | 1 |
| Varshney, A | 1 |
| Sharma, V | 1 |
| Zawar, V | 1 |
| Mumoli, N | 1 |
| Cei, M | 1 |
| Carmoi, T | 1 |
| Bordier, L | 1 |
| Bonnefoy, S | 1 |
| Callot, D | 1 |
| Lecoules, S | 1 |
| Algayres, JP | 1 |
| Johnson, L | 1 |
| Sabel, A | 1 |
| Burman, WJ | 1 |
| Everhart, RM | 1 |
| Rome, M | 1 |
| MacKenzie, TD | 1 |
| Rozwadowski, J | 1 |
| Mehler, PS | 1 |
| Price, CS | 1 |
| Cao, DY | 1 |
| Zhu, L | 1 |
| Wang, JH | 1 |
| Zhang, Y | 1 |
| Lajiness, MJ | 1 |
| Wagenlehner, FM | 2 |
| Wagenlehner, C | 2 |
| Weidner, W | 1 |
| Naber, KG | 11 |
| Koul, S | 1 |
| Bhan-Kotwal, S | 1 |
| Jenkins, HS | 1 |
| Carmaciu, CD | 1 |
| Llorens, L | 1 |
| Kotey, P | 2 |
| Hedrich, D | 1 |
| Lin, JN | 1 |
| Lai, CH | 1 |
| Chen, YH | 1 |
| Huang, CK | 1 |
| Lin, HF | 1 |
| Eng, HL | 1 |
| Lin, HH | 1 |
| Bartoletti, R | 1 |
| Cai, T | 1 |
| Zhang, YY | 1 |
| Huang, HH | 1 |
| Ren, ZY | 1 |
| Zheng, HG | 1 |
| Yu, YS | 1 |
| Lü, XJ | 1 |
| Xiao, ZK | 1 |
| Yang, HF | 1 |
| Xiu, QY | 1 |
| Chen, BY | 1 |
| Yue, HM | 1 |
| Hao, QL | 1 |
| Huang, JA | 1 |
| Ma, H | 1 |
| Xiao, W | 1 |
| Guo, DY | 1 |
| Si, B | 1 |
| Sun, SH | 1 |
| Zhang, W | 1 |
| Li, QH | 1 |
| Shen, HH | 1 |
| Duan, J | 1 |
| Li, HY | 1 |
| Yao, WZ | 1 |
| Gu, JM | 1 |
| Xia, QM | 1 |
| Ying, KJ | 1 |
| Liu, A | 1 |
| Yang, HP | 1 |
| Shi, MH | 1 |
| Sun, TY | 1 |
| Ding, GH | 1 |
| Wu, GM | 1 |
| Yamaguchi, K | 2 |
| Ohno, A | 1 |
| Ishii, Y | 1 |
| Tateda, K | 1 |
| Iwata, M | 2 |
| Kanda, M | 2 |
| Akizawa, K | 1 |
| Shimizu, C | 1 |
| Kon, S | 1 |
| Nakamura, K | 1 |
| Matsuda, K | 1 |
| Tominaga, M | 1 |
| Nakagawa, T | 1 |
| Sugita, A | 1 |
| Ito, T | 1 |
| Kato, J | 1 |
| Suwabe, A | 1 |
| Yamahata, K | 1 |
| Kawamura, C | 2 |
| Tashiro, H | 2 |
| Horiuchi, H | 2 |
| Katayama, Y | 1 |
| Kondou, S | 1 |
| Misawa, S | 1 |
| Murata, M | 1 |
| Kobayashi, Y | 1 |
| Okamoto, H | 1 |
| Yamazaki, K | 1 |
| Okada, M | 1 |
| Haruki, K | 1 |
| Kanno, H | 1 |
| Aihara, M | 1 |
| Maesaki, S | 1 |
| Hashikita, G | 1 |
| Miyajima, E | 1 |
| Sumitomo, M | 1 |
| Saito, T | 1 |
| Yamane, N | 2 |
| Kawashima, C | 1 |
| Akiyama, T | 2 |
| Ieiri, T | 1 |
| Yamamoto, Y | 1 |
| Okamoto, Y | 1 |
| Okabe, H | 1 |
| Moro, K | 1 |
| Shigeta, M | 1 |
| Yoshida, H | 2 |
| Yamashita, M | 1 |
| Hida, Y | 1 |
| Takubo, T | 1 |
| Kusakabe, T | 1 |
| Masaki, H | 1 |
| Heijyou, H | 1 |
| Nakaya, H | 1 |
| Kawahara, K | 1 |
| Sano, R | 1 |
| Matsuo, S | 1 |
| Kono, H | 1 |
| Yuzuki, Y | 1 |
| Ikeda, N | 1 |
| Idomuki, M | 1 |
| Soma, M | 1 |
| Yamamoto, G | 1 |
| Kinoshita, S | 2 |
| Kawano, S | 1 |
| Oka, M | 1 |
| Kusano, N | 1 |
| Kang, D | 1 |
| Ono, J | 2 |
| Yasujima, M | 2 |
| Miki, M | 1 |
| Hayashi, M | 1 |
| Okubo, S | 1 |
| Toyoshima, S | 2 |
| Kaku, M | 2 |
| Sekine, I | 1 |
| Shiotani, J | 1 |
| Tazawa, Y | 2 |
| Yoneyama, A | 1 |
| Kumasaka, K | 1 |
| Koike, K | 1 |
| Taniguchi, N | 1 |
| Ozaki, Y | 1 |
| Uchida, T | 1 |
| Murakami, M | 1 |
| Inuzuka, K | 1 |
| Gonda, H | 1 |
| Yamaguchi, I | 1 |
| fujimoto, Y | 1 |
| Iriyama, J | 1 |
| Asano, Y | 1 |
| Genma, H | 1 |
| Maekawa, M | 1 |
| Yoshimura, H | 1 |
| Nakatani, K | 1 |
| Baba, H | 1 |
| Ichiyama, S | 1 |
| Fujita, S | 1 |
| Kuwabara, M | 2 |
| Okazaki, T | 1 |
| Fujiwara, H | 1 |
| Ota, H | 1 |
| Nagai, A | 1 |
| Fujita, J | 1 |
| Negayama, K | 2 |
| Sugiura, T | 1 |
| Kamioka, M | 1 |
| Murase, M | 1 |
| Nakasone, I | 2 |
| Okayama, A | 1 |
| Aoki, Y | 1 |
| Kusaba, K | 1 |
| Nakashima, Y | 1 |
| Miyanohara, H | 1 |
| Hiramatsu, K | 1 |
| Saikawa, T | 1 |
| Yanagihara, K | 1 |
| Matsuda, J | 1 |
| Kohno, S | 1 |
| Mashiba, K | 1 |
| Deguchi, T | 3 |
| Nakane, K | 1 |
| Yasuda, M | 3 |
| Shimizu, T | 1 |
| Monden, K | 1 |
| Arakawa, S | 5 |
| Matsumoto, T | 5 |
| Drago, L | 3 |
| Nicola, L | 2 |
| Mattina, R | 1 |
| De Vecchi, E | 2 |
| Mirone, V | 1 |
| Bush, LM | 1 |
| Kaye, D | 1 |
| Yasufuku, T | 2 |
| Shigemura, K | 4 |
| Shirakawa, T | 2 |
| Nakano, Y | 4 |
| Tanaka, K | 4 |
| Nishimura, K | 1 |
| Kawabata, M | 2 |
| Fujisawa, M | 4 |
| Khawcharoenporn, T | 1 |
| Vasoo, S | 1 |
| Ward, E | 1 |
| Singh, K | 1 |
| Rafat, C | 1 |
| Vimont, S | 1 |
| Ancel, PY | 1 |
| Xu-Dubois, YC | 1 |
| Mesnard, L | 1 |
| Ouali, N | 1 |
| Denis, M | 1 |
| Vandewalle, A | 1 |
| Rondeau, E | 1 |
| Hertig, A | 1 |
| Damiao, R | 1 |
| Davies, T | 1 |
| Seike, K | 1 |
| Hsueh, PR | 1 |
| Lau, YJ | 1 |
| Ko, WC | 1 |
| Liu, CY | 1 |
| Huang, CT | 1 |
| Yen, MY | 1 |
| Liu, YC | 1 |
| Lee, WS | 1 |
| Liao, CH | 1 |
| Peng, MY | 2 |
| Chen, CM | 1 |
| Chen, YS | 1 |
| Matsumoto, M | 2 |
| Yamamichi, F | 1 |
| Tiengrim, S | 1 |
| Phiboonbanakit, D | 1 |
| Thunyaharn, S | 1 |
| Tantisiriwat, W | 1 |
| Santiwatanakul, S | 1 |
| Susaengrat, W | 1 |
| Srisurat, N | 1 |
| Malithong, A | 1 |
| Srisangchan, P | 1 |
| Thamlikitkul, V | 1 |
| Petronella, P | 1 |
| Scorzelli, M | 1 |
| Fiore, A | 1 |
| Corbisiero, MC | 1 |
| Agresti, E | 1 |
| Esposito, S | 5 |
| Freda, F | 1 |
| Nemoto, C | 1 |
| Ikegami, Y | 1 |
| Shimada, J | 1 |
| Tsukada, Y | 1 |
| Abe, Y | 1 |
| Tase, C | 1 |
| Chen, Y | 1 |
| Yang, H | 1 |
| Lu, G | 1 |
| Wu, X | 1 |
| Huang, W | 1 |
| Wu, Y | 1 |
| Lv, X | 1 |
| Wu, G | 1 |
| Zhang, G | 1 |
| Li, Q | 1 |
| Sun, Y | 1 |
| Takeda, S | 1 |
| Imai, T | 1 |
| Chaki, Y | 1 |
| Kusano, E | 1 |
| Schaeffer, AJ | 1 |
| Griffith, BC | 1 |
| Morey, AF | 1 |
| Ali-Khan, MM | 1 |
| Canby-Hagino, E | 1 |
| Foley, JP | 1 |
| Rozanski, TA | 1 |
| Castiñeiras, AA | 1 |
| Pérez-Pascual, P | 1 |
| Zarranz, JE | 1 |
| Della-Latta, P | 1 |
| Herreras, A | 1 |
| Nettis, E | 1 |
| Giordano, D | 1 |
| Pierluigi, T | 1 |
| Ferrannini, A | 1 |
| Tursi, A | 1 |
| Muratani, T | 1 |
| Iihara, K | 1 |
| Nishimura, T | 1 |
| Inatomi, H | 1 |
| Fujimoto, N | 1 |
| Kobayashi, T | 2 |
| Yamada, Y | 1 |
| Takahashi, K | 1 |
| Ramalakshmi, S | 1 |
| Bastacky, S | 1 |
| Johnson, JP | 1 |
| Matsuzaki, K | 1 |
| Watabe, E | 1 |
| Yoshimori, K | 1 |
| Shikano, M | 1 |
| Sato, Y | 1 |
| Hasegawa, M | 1 |
| Kobayashi, I | 1 |
| Noviello, S | 4 |
| Ianniello, F | 3 |
| Leone, S | 4 |
| Trinchieri, A | 2 |
| Marchetti, F | 3 |
| Tam, VK | 1 |
| Kung, WH | 1 |
| Li, R | 1 |
| Chan, KW | 1 |
| Knopf, HJ | 1 |
| Graff, HJ | 1 |
| Schulze, H | 1 |
| Bibb, JL | 1 |
| Servilla, KS | 1 |
| Gibel, LJ | 1 |
| Kinne, JE | 1 |
| White, RE | 1 |
| Hartshsorne, MF | 1 |
| Tzamaloukas, AH | 1 |
| Derevianko, II | 2 |
| Kahan, NR | 2 |
| Chinitz, DP | 2 |
| Kahan, E | 2 |
| Gopalachar, A | 1 |
| Akins, RL | 1 |
| Davis, WR | 1 |
| Siddiqui, AA | 1 |
| Padeĭskaia, EN | 1 |
| Weber, P | 2 |
| Dib, C | 1 |
| Durand, C | 1 |
| Moniot-Ville, N | 1 |
| Mahamat, A | 1 |
| Lavigne, JP | 1 |
| Fabbro-Peray, P | 1 |
| Kinowski, JM | 1 |
| Daurès, JP | 1 |
| Sotto, A | 1 |
| Schinzel, S | 1 |
| Slavov, Ch | 1 |
| Markova, B | 1 |
| Bovianska, N | 1 |
| Proevska, Iu | 1 |
| Chukov, I | 1 |
| Panchev, P | 1 |
| Yang, L | 1 |
| Hu, J | 1 |
| Wei, H | 1 |
| Wang, L | 1 |
| Zhong, H | 1 |
| Sidorenko, SV | 1 |
| Ivanov, DV | 2 |
| Azadian, BS | 1 |
| Talboys, CA | 1 |
| Roberts, AP | 1 |
| Tanphaichitra, D | 4 |
| Srimuang, S | 4 |
| Marone, P | 1 |
| Concia, E | 2 |
| Quarta, V | 1 |
| Minoli, L | 1 |
| Carnevale, G | 1 |
| Vogt, P | 1 |
| Schorn, T | 1 |
| Repp, H | 1 |
| Frei, U | 1 |
| Pichlmayr, R | 1 |
| Hansen, GT | 1 |
| Blondeau, JM | 1 |
| Serra, AL | 1 |
| Klein, M | 1 |
| Nitsch, D | 1 |
| Dürr, D | 1 |
| Wermuth, B | 1 |
| Frey, FJ | 1 |
| Makaryus, AN | 1 |
| Byrns, K | 1 |
| Makaryus, MN | 1 |
| Natarajan, U | 1 |
| Singer, C | 1 |
| Goldner, B | 1 |
| Ascione, T | 1 |
| Gaeta, GB | 1 |
| Kanbay, M | 1 |
| Aydogan, T | 1 |
| Bozalan, R | 1 |
| Isik, A | 1 |
| Uz, B | 1 |
| Kaya, A | 1 |
| Akcay, A | 1 |
| Tenke, P | 1 |
| Kovacs, B | 1 |
| Benkõ, R | 1 |
| Ashaber, D | 1 |
| Nagy, E | 1 |
| Roghmann, MC | 1 |
| Wallin, MT | 1 |
| Gorman, PH | 1 |
| Johnson, JA | 1 |
| Zaigraykin, N | 1 |
| Kovalev, J | 1 |
| Elias, N | 1 |
| Naschitz, JE | 1 |
| Marvaso, A | 1 |
| Gualco, L | 1 |
| Schito, AM | 1 |
| Schito, GC | 1 |
| Marchese, A | 1 |
| Topkaya, AE | 1 |
| Ozakkaş, F | 1 |
| Aksungar, FB | 1 |
| Tülbek, Y | 1 |
| Budanov, SV | 2 |
| Yamamoto, A | 1 |
| Konishi, I | 1 |
| Kumata, M | 1 |
| Isik, SR | 1 |
| Karakaya, G | 1 |
| Erkin, G | 1 |
| Kalyoncu, AF | 1 |
| Miura, T | 1 |
| Takenaka, A | 1 |
| Matsui, T | 1 |
| Kamidono, S | 1 |
| Kosan, M | 1 |
| Gonulalan, U | 1 |
| Ozturk, B | 1 |
| Kulacoglu, S | 1 |
| Erguder, I | 1 |
| Akdemir, O | 1 |
| Cetinkaya, M | 1 |
| Peterson, J | 2 |
| Kaul, S | 2 |
| Khashab, M | 2 |
| Fisher, A | 1 |
| Kahn, JB | 3 |
| Fisher, AC | 1 |
| Shigehara, K | 1 |
| Miyagi, T | 1 |
| Nakashima, T | 1 |
| Shimamura, M | 1 |
| Kishi, H | 1 |
| Nito, H | 1 |
| Saito, I | 2 |
| Nishimura, Y | 1 |
| Niijima, T | 1 |
| Ohmori, H | 1 |
| Tanaka, H | 1 |
| Fujita, Y | 1 |
| Deguchi, K | 1 |
| Ogawa, N | 1 |
| Morimoto, S | 1 |
| Hirano, A | 1 |
| Ohkawa, T | 1 |
| Doi, J | 1 |
| Suzuki, A | 1 |
| Hagino, K | 1 |
| Kitamura, S | 1 |
| Sawada, Y | 1 |
| Morita, T | 1 |
| Miyazaki, Y | 2 |
| Fica, AE | 1 |
| Horowitz, HW | 1 |
| Lior, H | 1 |
| Cabello, FC | 1 |
| Plaisance, JJ | 1 |
| Mancy, C | 1 |
| Li, Z | 1 |
| Chen, G | 1 |
| Zhuo, HT | 1 |
| Jones, RN | 3 |
| Hoban, DJ | 1 |
| Raz, R | 4 |
| Rottensterich, E | 1 |
| Leshem, Y | 1 |
| Tabenkin, H | 1 |
| Pfau, A | 2 |
| Sacks, TG | 2 |
| Simşek, F | 1 |
| Dillioğlugil, O | 1 |
| Ilker, Y | 1 |
| Akdaş, A | 1 |
| Hou, SR | 1 |
| Spivey, IM | 1 |
| Sigl, G | 1 |
| Fukuoka, Y | 1 |
| Ikeda, Y | 1 |
| Yamashiro, Y | 1 |
| Takahata, M | 1 |
| Todo, Y | 1 |
| Narita, H | 1 |
| Fujita, K | 2 |
| Matsuoka, N | 1 |
| Takenaka, I | 1 |
| Hiraishi, K | 1 |
| Yokota, T | 1 |
| Asahi, T | 2 |
| Tatara, K | 1 |
| Yuasa, M | 1 |
| Kaifu, Y | 1 |
| Kawano, A | 1 |
| Kawada, Y | 2 |
| Lee, SE | 1 |
| Chen, C | 1 |
| Limson, BM | 1 |
| Chan, P | 1 |
| Kongkanand, A | 1 |
| Wudhikarn, S | 1 |
| Tung, KH | 1 |
| Rahardjo, P | 1 |
| McCue, JD | 1 |
| Gaziano, P | 1 |
| Orders, D | 1 |
| Madsen, PO | 1 |
| Malek, GH | 1 |
| Owan, T | 1 |
| Rozenfeld, S | 1 |
| Liudvig, G | 1 |
| Navashin, SM | 1 |
| Navashin, PS | 1 |
| Smirnova, LB | 2 |
| Tsuchimori, N | 1 |
| Yamazaki, T | 1 |
| Okonogi, K | 1 |
| Ozeki, S | 1 |
| Nakano, M | 1 |
| Kawamura, T | 1 |
| Nishino, Y | 1 |
| Preston, SL | 1 |
| Drusano, GL | 1 |
| Berman, AL | 1 |
| Fowler, CL | 2 |
| Chow, AT | 1 |
| Dornseif, B | 1 |
| Reichl, V | 1 |
| Natarajan, J | 1 |
| Corrado, M | 1 |
| Martin, SJ | 2 |
| Meyer, JM | 1 |
| Chuck, SK | 1 |
| Jung, R | 2 |
| Messick, CR | 1 |
| Pendland, SL | 1 |
| Klimberg, IW | 1 |
| Cox, CE | 3 |
| King, W | 1 |
| Kim, SS | 1 |
| Callery-D'Amico, S | 1 |
| Henry, D | 1 |
| Ellison, W | 1 |
| Sullivan, J | 1 |
| Mansfield, DL | 1 |
| Magner, DJ | 1 |
| Dorr, MB | 1 |
| Talbot, GH | 1 |
| Shandera, KC | 1 |
| Thibault, GP | 1 |
| Deshon, GE | 1 |
| Langtry, HD | 1 |
| Lamb, HM | 2 |
| Khodyreva, LA | 1 |
| Avdoshin, VL | 1 |
| Andriukhin, MI | 1 |
| Gabliia, MIu | 1 |
| Onrust, SV | 1 |
| Balfour, JA | 1 |
| McCarty, JM | 1 |
| Richard, G | 1 |
| Huck, W | 1 |
| Tucker, RM | 1 |
| Tosiello, RL | 1 |
| Shan, M | 1 |
| Heyd, A | 1 |
| Echols, RM | 1 |
| Bagon, JA | 1 |
| Fünfstück, R | 1 |
| Wolfram, M | 1 |
| Gerth, J | 1 |
| Schubert, K | 1 |
| Straube, E | 1 |
| Stein, G | 1 |
| Redondo Sánchez, J | 1 |
| Isen, K | 1 |
| Küpeli, B | 1 |
| Sinik, Z | 1 |
| Sözen, S | 1 |
| Bozkirli, I | 1 |
| Hooper, DC | 3 |
| Miedouge, M | 1 |
| Hacini, J | 1 |
| Grimont, F | 1 |
| Watine, J | 1 |
| Kadiri, S | 1 |
| Ajayi, SO | 1 |
| Toki, RA | 1 |
| Reid, G | 2 |
| Potter, P | 1 |
| Delaney, G | 1 |
| Hsieh, J | 1 |
| Nicosia, S | 1 |
| Hayes, K | 1 |
| Raizenberg, C | 1 |
| Rohana, Y | 1 |
| Unamba-Oparah, I | 1 |
| Korfman, G | 1 |
| Yaniv, I | 1 |
| Asvanich, K | 1 |
| Fugpholngam, V | 1 |
| Miyazaki, S | 1 |
| Kashitani, F | 1 |
| Tsujio, Y | 1 |
| Okada, J | 1 |
| Watanabe, N | 1 |
| Uehara, N | 1 |
| Igari, J | 1 |
| Oguri, T | 1 |
| Kaimori, M | 1 |
| Iinuma, Y | 1 |
| Nisawataira, T | 1 |
| Ueno, K | 1 |
| Ishigo, S | 1 |
| Kawahara, S | 1 |
| Itoh, C | 1 |
| Yoshida, T | 1 |
| Yamanaka, K | 1 |
| Katoh, J | 1 |
| Kudoh, M | 1 |
| Matsushima, T | 1 |
| Niki, Y | 1 |
| Miyashita, N | 1 |
| Funato, T | 1 |
| Sato, N | 1 |
| Saito, Y | 2 |
| Ishii, K | 1 |
| Hongo, T | 1 |
| Kamihira, S | 1 |
| Takii, M | 1 |
| Ishii, M | 1 |
| Nakagawa, K | 1 |
| Takada, T | 1 |
| Murakami, N | 1 |
| Taira, M | 1 |
| Tamaki, I | 1 |
| Matsudou, Y | 1 |
| Hollauer, K | 1 |
| Kirchbauer, D | 1 |
| Witte, W | 1 |
| Kamei, T | 1 |
| Toriumi, Y | 1 |
| Tomioka, H | 1 |
| Scheen, AJ | 1 |
| Abell, S | 1 |
| Chapman, S | 1 |
| Nadin, L | 1 |
| Warren, R | 1 |
| Habash, M | 1 |
| Vachon, D | 1 |
| Denstedt, J | 1 |
| Riddell, J | 1 |
| Beheshti, M | 1 |
| Garvin, CG | 1 |
| Paltoo, B | 1 |
| O'Donoghue, S | 1 |
| Mousavi, MS | 1 |
| Mombelli, B | 1 |
| Valli, M | 1 |
| Gismondo, MR | 1 |
| Gupta, K | 1 |
| Hooton, TM | 1 |
| Roberts, PL | 1 |
| Stamm, WE | 1 |
| Mavromanolakis, E | 1 |
| Maraki, S | 1 |
| Cranidis, A | 1 |
| Tselentis, Y | 1 |
| Kontoyiannis, DP | 1 |
| Samonis, G | 1 |
| Spahr, L | 1 |
| Rubbia-Brandt, L | 1 |
| Marinescu, O | 1 |
| Armenian, B | 1 |
| Hadengue, A | 1 |
| Chen, J | 1 |
| Chen, RR | 1 |
| Huang, HS | 1 |
| Vasil'ev, AN | 1 |
| Beach, ML | 1 |
| Pfaller, MA | 1 |
| Trinchiere, A | 1 |
| Hayashi, T | 1 |
| Sakai, Y | 1 |
| Saito, K | 1 |
| Arai, G | 1 |
| Hyochi, N | 1 |
| Suzuki, M | 1 |
| Masuda, H | 1 |
| Kawakami, S | 1 |
| Okuno, T | 1 |
| Kageyama, Y | 1 |
| Kihara, K | 1 |
| Baskin, H | 1 |
| Doğan, Y | 1 |
| Bahar, IH | 1 |
| Yuluğ, N | 2 |
| Loran, OB | 1 |
| Pushkar', DIu | 1 |
| Rasner, PI | 1 |
| Boukadida, J | 1 |
| Boukadida, N | 1 |
| Elraii, S | 1 |
| Mangiarotti, B | 1 |
| Lizzano, R | 1 |
| Thyroff-Friesinger, U | 2 |
| Liassine, N | 1 |
| Chelfi, A | 1 |
| Rahal, K | 1 |
| Morita, M | 2 |
| Ito, S | 1 |
| Suzuki, K | 4 |
| Spencer, RC | 1 |
| Cole, TP | 1 |
| Kumazawa, J | 2 |
| Fennig, S | 1 |
| Mauas, L | 1 |
| Bravo, JL | 1 |
| Horiba, M | 1 |
| Reller, LB | 1 |
| Rosati, LA | 1 |
| Erwin, ME | 1 |
| Sanchez, ML | 1 |
| Ozaki, M | 1 |
| Matsuda, M | 1 |
| Tomii, Y | 1 |
| Kimura, K | 1 |
| Segawa, J | 1 |
| Kitano, M | 1 |
| Kise, M | 1 |
| Shibata, K | 1 |
| Otsuki, M | 1 |
| Nishino, T | 3 |
| Hasuda, A | 1 |
| Peled, Y | 1 |
| Friedman, S | 1 |
| Hod, M | 1 |
| Merlob, P | 1 |
| Kiliç, H | 1 |
| Karahan, M | 1 |
| Basista, MP | 1 |
| Corrado, ML | 1 |
| Nicolle, LE | 1 |
| Degelau, J | 1 |
| Alessi, P | 1 |
| Cullison, J | 1 |
| Meyers, B | 1 |
| Ueda, S | 1 |
| Eto, K | 1 |
| Yushita, Y | 1 |
| Ishii, T | 1 |
| Sawae, Y | 1 |
| Biglino, A | 1 |
| Forno, B | 1 |
| Pollono, AM | 1 |
| Busso, M | 1 |
| Arpinelli, F | 1 |
| Benedetti, M | 1 |
| Pugliese, A | 1 |
| Oksa, A | 1 |
| Dzúriková, V | 1 |
| Gajdos, M | 1 |
| Krechnáková, A | 1 |
| Krivosíková, G | 1 |
| Ploczeková, C | 1 |
| Spustová, V | 1 |
| Kromann-Andersen, B | 3 |
| Krøyer Nielsen, K | 1 |
| Uchibayashi, T | 1 |
| Nishino, A | 1 |
| Motoi, I | 1 |
| Hisazumi, H | 1 |
| Sawaki, M | 1 |
| Orito, M | 1 |
| Koizumi, H | 1 |
| Shyoda, R | 1 |
| Nagano, K | 1 |
| Kobashi, K | 1 |
| Regamey, C | 1 |
| Steinbach-Lebbin, C | 1 |
| Mouton, Y | 1 |
| Leroy, O | 1 |
| Beuscart, C | 1 |
| Sivery, B | 1 |
| Senneville, E | 1 |
| Chidiac, C | 1 |
| Beaucaire, G | 1 |
| Vincent du Laurier, M | 1 |
| Schalkhäuser, K | 1 |
| Adam, D | 1 |
| Wittenberger, R | 2 |
| Bartosik-Wich, B | 1 |
| Unal, S | 2 |
| Aydin, M | 2 |
| Ozaydin, N | 1 |
| Akin, A | 1 |
| Dervişoğlu, AA | 1 |
| Kawamura, N | 1 |
| Nakajima, N | 1 |
| Hoshino, H | 1 |
| Tanaka, M | 1 |
| Koinuma, A | 1 |
| Waldvogel, FA | 1 |
| Bottino, G | 1 |
| Marinello, M | 1 |
| Menna, C | 1 |
| Vergano, RM | 1 |
| Obana, Y | 2 |
| Nakamura, S | 1 |
| Minami, A | 1 |
| Nakata, K | 1 |
| Kurobe, N | 1 |
| Kouno, K | 1 |
| Sakaguchi, Y | 1 |
| Kashimoto, S | 1 |
| Kojima, T | 1 |
| Ohue, T | 1 |
| Kullich, W | 1 |
| Brugger, P | 1 |
| Klein, G | 1 |
| Neu, HC | 2 |
| Wolfson, JS | 1 |
| Hirai, K | 1 |
| Aoyama, H | 1 |
| Hosaka, M | 1 |
| Oomori, Y | 1 |
| Niwata, Y | 1 |
| Suzue, S | 1 |
| Irikura, T | 1 |
| Belovezhdov, N | 1 |
| Angelova, I | 1 |
| Talakova, Ch | 1 |
| Sahaphong, S | 1 |
| Marty, N | 1 |
| Clave, D | 1 |
| Cancet, B | 1 |
| Henry-Ferry, S | 1 |
| Didier, J | 1 |
| Osman, LM | 1 |
| Sabbour, MS | 2 |
| el-Baz, F | 1 |
| Matsuura, T | 1 |
| Kurita, T | 1 |
| Yoshida, K | 1 |
| Takahashi, T | 1 |
| Nakame, Y | 1 |
| Saitoh, H | 1 |
| Negishi, T | 1 |
| Horiuchi, S | 1 |
| Kaneoya, F | 1 |
| Tari, K | 1 |
| Satake, I | 1 |
| Kojima, S | 1 |
| Prát, V | 1 |
| Horcicková, M | 1 |
| Matousovic, K | 1 |
| Hatala, M | 1 |
| Janda, P | 1 |
| Milotová, Z | 1 |
| Horácková, M | 1 |
| Osten, J | 1 |
| Potuzník, V | 1 |
| Akazawa, N | 1 |
| Tsugawa, M | 1 |
| Hayata, S | 1 |
| Sasaki, H | 1 |
| Okita, K | 1 |
| Sommer, P | 2 |
| Pers, C | 2 |
| Larsen, V | 2 |
| Rasmussen, F | 2 |
| Piccolomini, R | 1 |
| Cellini, L | 1 |
| Allocati, N | 1 |
| Di Girolamo, A | 1 |
| Selan, L | 1 |
| Scazzocchio, F | 1 |
| Munakata, A | 1 |
| Genesin, J | 1 |
| Gonen, E | 1 |
| Shmilovitz, M | 1 |
| Hefter, H | 1 |
| Potasman, I | 1 |
| Tunçkanat, F | 1 |
| Bertrand, A | 1 |
| Janbon, F | 1 |
| Despaux, E | 1 |
| Jonquet, O | 1 |
| Reynes, J | 1 |
| Ode, B | 1 |
| Walder, M | 1 |
| Forsgren, A | 1 |
| Hasçelik, G | 1 |
| Schulz, W | 1 |
| Dörfler, A | 1 |
| Delia, S | 1 |
| De Simone, C | 1 |
| Vullo, V | 1 |
| Sorice, F | 1 |
| el-Baz, W | 1 |
| Osman, L | 1 |
| Abd-el-Hamid, T | 1 |
| el-Bokl, M | 1 |
| Miyata, M | 1 |
| Inagaki, N | 1 |
| Inada, F | 1 |
| Yachiku, S | 1 |
| Okamura, K | 1 |
| Osanai, H | 1 |
| Mizunaga, M | 1 |
| Morikawa, M | 1 |
| Nishio, S | 1 |
| Yoshihara, H | 1 |
| Petersen, EE | 1 |
| de Isele, TS | 1 |
| Pelz, K | 1 |
| Weiss, N | 1 |
| Rugendorff, EW | 1 |
| Vellucci, A | 1 |
| Bernardini, G | 1 |
| Battaglia, AM | 1 |
| Battaglia, P | 1 |
| Fröhlich, G | 1 |
| Stratmeyer, R | 1 |
| Blomer, R | 1 |
| Bruch, K | 1 |
| Zahlten, RN | 1 |
| Rubinstein, E | 1 |
| Mark, Z | 1 |
| Keren, G | 1 |
| Alkan, M | 1 |
| Berger, S | 1 |
| Bogokowski, B | 1 |
| Guibert, J | 1 |
| Acar, JF | 1 |
| Cynamon, MH | 1 |
| Wilcox, GH | 1 |
| Grassi, GG | 1 |
| Callery, SV | 1 |
| Tack, KJ | 1 |
| Altay, G | 1 |
| Tulunay, C | 1 |
| Tamai, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Non-Inferiority Study for Shortening Tuberculosis Treatment With Sitafloxacin-Containing Regimens[NCT05454345] | Phase 3 | 620 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Verus a Comparator Antibiotic in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis[NCT00229021] | Phase 3 | 741 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| A Multicenter, Phase 3 Study of the Safety and Effectiveness of Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis[NCT00210990] | Phase 3 | 403 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| [NCT02729116] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2016-07-31 | Active, not recruiting | ||
| Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer: a Phase III Randomized Trial[NCT03862170] | Phase 3 | 255 participants (Anticipated) | Interventional | 2015-02-10 | Suspended (stopped due to Covid-19 pandemic) | ||
| A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis[NCT00210886] | Phase 3 | 1,109 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)[NCT02650518] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole[NCT02734732] | Phase 2 | 2,800 participants (Anticipated) | Interventional | 2015-04-30 | Recruiting | ||
| Does Prophylaxis With Macrobid Reduce the Incidence of Urinary Tract Infection in Patients Who Receive a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence: Randomized, Double Blinded Placebo Controlled Clinical Trial[NCT00734968] | Phase 4 | 161 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The overall rate of UTI following the placement of sub-urethral sling for the treatment of stress urinary incontinence in our study was 24.8% (n = 37) (NCT00734968)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment | 13 |
| Placebo | 24 |
The incidence of UTI in the placebo group was 32%. (NCT00734968)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment | 13 |
| Placebo | 24 |
The incidence of UTI in the nitrofurantoin group was 17.6%. (NCT00734968)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment | 13 |
| Placebo | 24 |
23 reviews available for ofloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women.
Topics: Anti-Bacterial Agents; Asymptomatic Infections; Azithromycin; Chlamydia Infections; Chlamydia tracho | 2019 |
[From cystitis to bacterial prostatitis: experience with levofloxacin].
Topics: Anti-Bacterial Agents; Bacterial Infections; Cystitis; Double-Blind Method; Drug Therapy, Combinatio | 2009 |
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Ga | 2002 |
Renal parenchymal malacoplakia: a rare cause of ARF with a review of recent literature.
Topics: Acute Kidney Injury; Aged; Biopsy, Needle; Cefuroxime; Diagnosis, Differential; Drug Therapy, Combin | 2003 |
Levofloxacin in the treatment of urinary tract infections and prostatitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug | 2004 |
[Levofloxacin (Tavanic) and therapy of urogenital infections].
Topics: Animals; Female; Humans; Levofloxacin; Male; Ofloxacin; Urinary Tract Infections | 2004 |
[Levofloxacin and other antibacterial drugs].
Topics: Anti-Bacterial Agents; Bacterial Infections; Dermatitis; Dosage Forms; Humans; Levofloxacin; Ofloxac | 2006 |
Usefulness and problems of the urinary tract infection criteria for evaluating drug efficacy for complicated urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Amdinocillin Pivoxil; Anti-Infective Agents, Urinary; Cephalosporins | 2007 |
Fluoroquinolones reviewed.
Topics: Adult; Anti-Infective Agents; Child; Ciprofloxacin; Clinical Trials as Topic; Female; Humans; Norflo | 1993 |
[Ten-year experience with the use of ofloxacin (Tarivid*). New treatment regimens].
Topics: Anti-Infective Agents; Drug Administration Schedule; Humans; Ofloxacin; Respiratory Tract Infections | 1996 |
Levofloxacin and sparfloxacin: new quinolone antibiotics.
Topics: Absorption; Anti-Infective Agents; Bronchitis; Drug Interactions; Drug Resistance, Microbial; Fluoro | 1998 |
Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
Topics: Animals; Anti-Infective Agents; Humans; Levofloxacin; Ofloxacin; Respiratory Tract Infections; Skin | 1998 |
Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Drug Resistance; Female | 1998 |
[Levofloxacin for prevalent infections in primary care medicine].
Topics: Anti-Infective Agents; Bacterial Infections; Community-Acquired Infections; Humans; Levofloxacin; Of | 1999 |
New uses for new and old quinolones and the challenge of resistance.
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; M | 2000 |
The fluoroquinolones after ciprofloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Naphthyridines; Ofloxacin; Pi | 2000 |
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Microbial; Drug-Related Side Effects and Adverse Re | 2001 |
[The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
Topics: Acute Disease; Animals; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infec | 2001 |
[Role of levofloxacin in the treatment of urinary tract infections].
Topics: Anti-Infective Agents, Urinary; Female; Humans; Levofloxacin; Male; Ofloxacin; Prostatitis; Urinary | 2001 |
[Use of levofloxacin in the antibiotic prophylaxis for diagnostic procedures in urology].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinar | 2002 |
Worldwide clinical experience with ofloxacin in urologic cases.
Topics: Female; Global Health; Humans; Male; Ofloxacin; Urinary Tract Infections | 1991 |
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
Topics: Anti-Bacterial Agents; Bacteria; Blood Proteins; Ciprofloxacin; Enoxacin; Fluorine; Humans; Kidney; | 1985 |
The role of 4-quinolones in the treatment of infections.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Kinetics; Norfloxacin; Ofloxacin; Oxazines; Urinary Tra | 1987 |
74 trials available for ofloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Double-Blind Method; Fever; Humans; Male; Ofloxacin; U | 2023 |
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Female; Humans; Imipenem | 2013 |
Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Doripenem; Double-Blin | 2009 |
Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Double-Blind Method; Fema | 2009 |
Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.
Topics: Administration, Oral; Adolescent; Aged; Anti-Bacterial Agents; China; Dizziness; Drug Administration | 2009 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; | 2010 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; | 2010 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; | 2010 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; | 2010 |
Antibiotic prophylaxis in catheter-associated urinary infections.
Topics: Antibiotic Prophylaxis; Female; Humans; Levofloxacin; Male; Ofloxacin; Urinary Catheterization; Urin | 2012 |
Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Dioxolanes; Disk Diffusion Antimicrobial Tests; Doub | 2012 |
Single dose levofloxacin prophylaxis for prostate biopsy in patients at low risk.
Topics: Administration, Oral; Anti-Infective Agents, Urinary; Antibiotic Prophylaxis; Biopsy, Needle; Humans | 2002 |
[Faropenem 300 mg 3 times daily versus levofloxacin 100 mg 3 times daily in the treatment of urinary tract infections in patients with neurogenic bladder and/or benign prostatic hypertrophy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; b | 2002 |
[Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections].
Topics: Anti-Infective Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Enterobacteriaceae | 2003 |
Perioperative antibiotic prophylaxis in ureteroscopic stone removal.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antibiotic Prophylaxis; Dose-Response Relationship, D | 2003 |
Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate.
Topics: Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibiotic Prophylaxis; Bacteriuria; Dr | 2005 |
[Clinical significance of antibiotic prophylaxis for transrectal prostate biopsy].
Topics: Aged; Aged, 80 and over; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Drug Therapy, Combin | 2001 |
A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; | 2006 |
Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Community-Acquired Infections; Drug Administr | 2006 |
Usefulness and problems of the urinary tract infection criteria for evaluating drug efficacy for complicated urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Amdinocillin Pivoxil; Anti-Infective Agents, Urinary; Cephalosporins | 2007 |
Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Ciprof | 2007 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
[Comparative studies of DL-8280 and pipemidic acid in complicated urinary tract infections by double-blind method].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Clinical Trials as T | 1984 |
[Clinical study on antimicrobial prophylaxis following extracorporeal shock wave lithotripsy].
Topics: Adult; Bacteriuria; Cephalosporins; Female; Humans; Lithotripsy; Male; Middle Aged; Ofloxacin; Preme | 1995 |
Application of NONMEM method for evaluation of relative biological availability of ofloxacin.
Topics: Adult; Biological Availability; Female; Humans; Male; Middle Aged; Nonlinear Dynamics; Ofloxacin; Re | 1994 |
Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Cefixime; Cefotaxime; Double-Blin | 1994 |
Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women.
Topics: Adult; Ciprofloxacin; Coitus; Female; Humans; Norfloxacin; Ofloxacin; Prospective Studies; Recurrenc | 1994 |
[Clinical study of Chinese ofloxacin].
Topics: Adolescent; Adult; Aged; Female; Gonorrhea; Humans; Male; Middle Aged; Ofloxacin; Respiratory Tract | 1993 |
Single dose quinolone treatment in acute uncomplicated urinary tract infection in women.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Female; Gram-Negative Bacterial Infect | 1993 |
Fleroxacin versus ofloxacin in patients with complicated urinary tract infection: a controlled clinical study.
Topics: Adult; Aged; Aged, 80 and over; Female; Fleroxacin; Humans; Male; Middle Aged; Ofloxacin; Prospectiv | 1993 |
Pharmacokinetics of ofloxacin--measurement of drug concentration in saliva of patients with impaired renal function.
Topics: Anti-Infective Agents; Female; Humans; Kidney Diseases; Male; Middle Aged; Ofloxacin; Saliva; Urinar | 1995 |
Evaluation of clinical efficacy of antimicrobials in complicated urinary tract infections. Comparison of Japanese criteria with IDSA guidelines. Infectious Diseases Society of America.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteriuria; Female; Gram-Negative Bacteria; | 1995 |
A randomised controlled trial of ofloxacin 200 mg 4 times daily or twice daily vs ciprofloxacin 500 mg twice daily in elderly nursing home patients with complicated UTI.
Topics: Aged; Anti-Infective Agents; Biological Availability; Ciprofloxacin; Female; Humans; Male; Nursing H | 1995 |
Single dose UTI prophylaxis in transurethral surgery. Oral ofloxacin vs parenteral cefotaxime.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Cefotaxime; Cephalosp | 1995 |
3-day course of ofloxacin versus cefalexin in the treatment of urinary tract infections in postmenopausal women.
Topics: Aged; Anti-Infective Agents, Urinary; Cephalexin; Cephalosporins; Costs and Cost Analysis; Female; H | 1996 |
[Clinical experience with the use of ofloxacin in infections of the upper and lower urinary tracts: demonstrations of the results of clinical trials].
Topics: Anti-Infective Agents, Urinary; Dose-Response Relationship, Drug; Drug Administration Schedule; Fema | 1996 |
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Bayes Theorem; Dose-Response R | 1998 |
A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary; Female; Fluor | 1998 |
Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.
Topics: Acute Disease; Adolescent; Adult; Anti-Infective Agents; Community-Acquired Infections; Female; Fluo | 1998 |
Efficacy of one dose fluoroquinolone before prostate biopsy.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy, Needle; Costs and Cost Analysis; Follow-Up St | 1998 |
[Efficacy of lomefloxacin in treatment of nonspecific inflammatory diseases and in prophylaxis of postoperative complications in urology].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Female; F | 1998 |
A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary | 1999 |
Antibiotic prophylaxis for transrectal biopsy of the prostate: a prospective randomized study of the prophylactic use of single dose oral fluoroquinolone versus trimethoprim-sulfamethoxazole.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibiotic Prophy | 1999 |
Quinolones for short-term treatment of uncomplicated urinary tract infection.
Topics: 4-Quinolones; Administration, Oral; Adult; Anti-Infective Agents; Bacterial Infections; Female; Fluo | 1999 |
Ofloxacin for the treatment of urinary tract infections and biofilms in spinal cord injury.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Biofilms; Double-Blin | 2000 |
Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Method; Drug Administ | 2000 |
An open, non comparative study of ofloxacin i.v. on the treatment of acute symptomatic urinary tract infection.
Topics: Acute Disease; Adolescent; Adult; Aged; Bacterial Infections; Dose-Response Relationship, Drug; Drug | 2000 |
Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation.
Topics: Administration, Oral; Adsorption; Anti-Infective Agents; Anti-Infective Agents, Urinary; Biofilms; C | 2001 |
Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women.
Topics: Adult; Algorithms; Anti-Infective Agents, Urinary; Feasibility Studies; Female; Follow-Up Studies; H | 2001 |
Randomized, double-blind, comparative study of levofloxacin and ofloxacin in the treatment of complicated urinary tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Bacteria; Double-Blind Method; Female; Humans; Levofloxacin; Mal | 1999 |
[Tavanik effectiveness and safety in the treatment of urinary tract infection complications].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Male; Middle Aged; Of | 2001 |
Spectrum and susceptibility of pathogens causing acute uncomplicated lower UTI in females and its correlation to bacteriologic outcome after single dose therapy with fosfomycin trometamol versus ofloxacin/co-trimoxazole.
Topics: Acute Disease; Adolescent; Adult; Aged; Drug Administration Schedule; Female; Fosfomycin; Humans; Mi | 1992 |
Ofloxacin versus trimethoprim and co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice.
Topics: Adult; Aged; Escherichia coli Infections; Family Practice; Female; Humans; Male; Middle Aged; Ofloxa | 1992 |
[Study of the long-term administration of ofloxacin to the patients following transurethral resection of the prostate].
Topics: Aged; Drug Administration Schedule; Drug Evaluation; Humans; Male; Middle Aged; Ofloxacin; Postopera | 1991 |
Randomized study to evaluate efficacy and safety of ofloxacin vs. trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Ofloxacin; Superinfection; Trimet | 1991 |
Ofloxacin use in a geriatric population.
Topics: Aged; Cross Infection; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Ofloxacin; Pneumonia; | 1991 |
Treatment of complicated urinary tract infections with ofloxacin following an aminoglycoside.
Topics: Administration, Oral; Adolescent; Aged; Bacteriuria; Drug Therapy, Combination; Gentamicins; Humans; | 1991 |
Ofloxacin in urinary tract infections.
Topics: Administration, Oral; Drug Administration Schedule; Half-Life; Humans; Ofloxacin; Time Factors; Urin | 1990 |
[Clinical evaluation of ofloxacin in the treatment of chronic complicated urinary tract infection].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Humans; M | 1990 |
Fosfomycin trometamol versus ofloxacin/co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study.
Topics: Adolescent; Adult; Aged; Bacteriuria; Drug Administration Schedule; Drug Therapy, Combination; Drug | 1990 |
Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study.
Topics: Adolescent; Adult; Aged; Female; Gastrointestinal Diseases; Humans; Injections, Intravenous; Male; M | 1990 |
Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Female; Fran | 1990 |
Comparison of i.v. ofloxacin and piperacillin in the treatment of complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Gram-Negative Bacteria; Humans; Injections, Intr | 1990 |
[Single-dose amoxicillin, TMP-SMX and ofloxacin therapy in lower urinary tract infections].
Topics: Adult; Amoxicillin; Female; Humans; Middle Aged; Ofloxacin; Trimethoprim, Sulfamethoxazole Drug Comb | 1989 |
[Use of ofloxacin in 45 cases of infection of the lower urinary tract in women].
Topics: Adult; Drug Administration Schedule; Drug Evaluation; Female; Humans; Middle Aged; Ofloxacin; Urinar | 1989 |
Ofloxacin in the management of complicated urinary tract infections, including prostatitis.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Carbenicillin; Drug Resistance, Microbial; | 1989 |
[Clinical trial of ofloxacin (Tarivid R)].
Topics: Adult; Aged; Bacterial Infections; Clinical Trials as Topic; Drug Resistance, Microbial; Female; Hum | 1988 |
Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Female; Gonorrhea; Humans; Male; Middle Aged; Ofloxa | 1986 |
Ofloxacin compared with ciprofloxacin in the treatment of complicated lower urinary tract infections.
Topics: Ciprofloxacin; Double-Blind Method; Humans; Ofloxacin; Prospective Studies; Random Allocation; Urina | 1988 |
Failure of a single dose of 100 mg ofloxacin in lower urinary tract infections in females.
Topics: Anti-Infective Agents, Urinary; Clinical Trials as Topic; Drug Combinations; Escherichia coli Infect | 1987 |
Open randomised comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections.
Topics: Adult; Anti-Infective Agents; Bacteriuria; Female; Humans; Male; Microbial Sensitivity Tests; Norflo | 1987 |
Ofloxacin vs. cotrimoxazole in patients with complicated urinary tract infections.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Drug Combinations; Female; Humans; Male; Middle Aged; O | 1987 |
[Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe].
Topics: Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Drug Evaluation; Drug Resista | 1986 |
[Ofloxacin versus pipemidic acid and co-trimoxazole].
Topics: Adult; Anti-Infective Agents, Urinary; Bacteria; Bacterial Infections; Clinical Trials as Topic; Dos | 1986 |
A multicenter study on clinical efficacy of ofloxacin in respiratory and urinary tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Ofl | 1986 |
Clinical experience with ofloxacin in urinary tract infection.
Topics: Anti-Infective Agents; Clinical Trials as Topic; Drug Combinations; Female; Humans; Male; Ofloxacin; | 1986 |
Clinical evaluation of ofloxacin versus ciprofloxacin in complicated urinary tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; | 1986 |
139 other studies available for ofloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
Topics: Bacterial Proteins; Chromosomes, Bacterial; Electrophoresis, Gel, Pulsed-Field; Methicillin Resistan | 2008 |
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Cells, Cultured; Drug Resistan | 2010 |
Assessment of Bacterial Isolates from the Urine Specimens of Urinary Tract Infected Patient.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli | 2022 |
Evolution of antibiotic treatments for healthcare-associated infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in France.
Topics: Aminoglycosides; Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cla | 2022 |
Standardised antenatal antibiotic regimens and neonatal sepsis-Are we certain we have it right?
Topics: Anti-Bacterial Agents; Female; Humans; Neonatal Sepsis; Ofloxacin; Pregnancy; Quinolones; Urinary Tr | 2020 |
Anaphylactic shock secondary to oral ofloxacin administration with cross-reactivity to levofloxacin and ciprofloxacin.
Topics: Administration, Oral; Adolescent; Anaphylaxis; Ciprofloxacin; Cross Reactions; Drug Hypersensitivity | 2018 |
A rare case of facial annular bullous erythema nodosum leprosum reaction in a young boy.
Topics: Adolescent; Anti-Infective Agents, Urinary; Drug Eruptions; Erythema Nodosum; Humans; Leprosy, Lepro | 2016 |
A case of purple urine.
Topics: Aged, 80 and over; Anti-Infective Agents, Urinary; Dehydration; Female; Humans; Hypernatremia; Oflox | 2009 |
[Ofloxacin is contraindicated in case of G6PD deficiency: is it evidenced based?].
Topics: Contraindications; Diabetes Complications; Escherichia coli Infections; Female; Glucosephosphate Deh | 2009 |
Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Drug Resist | 2008 |
[Prevention of peri-operative infection with levofloxacin in female patients undergoing surgery for stress urinary incontinence].
Topics: Administration, Oral; Anti-Bacterial Agents; Antibiotic Prophylaxis; Drug Administration Schedule; F | 2008 |
Common antibiotics for the treatment of urinary tract infections.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Costs; Humans; Nitrofurantoin; Nurse's Role; Ofloxacin; P | 2008 |
Organic psychosis induced by ofloxacin and metronidazole.
Topics: Adolescent; Anti-Infective Agents; Antipsychotic Agents; Citalopram; Drug Therapy, Combination; Fema | 2009 |
Urinary Mycobacterium szulgai infection in an immunocompetent patient.
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Immunocompetence; Isoniazid; Levof | 2009 |
[Chronic prostatitis and biofilm].
Topics: Adult; Biofilms; Chronic Disease; Ciprofloxacin; Contraception Behavior; Diet; Disease Susceptibilit | 2009 |
[In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007].
Topics: Anti-Bacterial Agents; Bacteria; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; G | 2009 |
Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Computer Simulation; Female; H | 2010 |
In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Dioxolanes; DNA Gyrase; DNA Mutational Ana | 2010 |
Catheter-associated urinary tract infection IDSA guidelines: why the levofloxacin?
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Catheter-Related Infections; Humans; Levofloxacin; Of | 2010 |
Risk factors and mechanisms of fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, B | 2011 |
High rates of quinolone resistance among urinary tract infections in the ED.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents | 2012 |
Ofloxacin: new applications for the prevention of urinary tract infections in renal graft recipients.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Dru | 2011 |
Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Area Under Curve; Computer Simulation; Databases, Factual; Escherichia coli; | 2011 |
Consensus statement on the role of fluoroquinolones in the management of urinary tract infections.
Topics: Anti-Bacterial Agents; Consensus Development Conferences as Topic; Drug Resistance, Bacterial; Esche | 2011 |
Mechanisms of and risk factors for fluoroquinolone resistance in clinical Enterococcus faecalis isolates from patients with urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resist | 2011 |
Relationship between urinary tract infection categorization and pathogens' antimicrobial susceptibilities.
Topics: Anti-Infective Agents; Catheter-Related Infections; Ceftazidime; Enterococcus faecalis; Escherichia | 2012 |
Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxaci | 2012 |
Acute renal failure caused by severe coagulopathy induced by the interaction between warfarin potassium and levofloxacin: a case report.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Anticoagulants; Blood Coagulation Disorders; Card | 2012 |
Four consecutive cases of Achilles tendon disorders associated with levofloxacin treatment in hemodialysis patients.
Topics: Achilles Tendon; Administration, Oral; Aged; Anti-Infective Agents, Urinary; Dose-Response Relations | 2012 |
Bacteriological conversion in twenty urinary tuberculosis patients treated with ofloxacin, rifampin and isoniazid: a 10-year follow-up study.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Antitubercular Agents; Drug Therapy, Combination; Femal | 2002 |
Erythema multiforme-like rash in a patient sensitive to ofloxacin.
Topics: Adrenal Cortex Hormones; Adult; Conjunctivitis, Bacterial; Drug Hypersensitivity; Drug Therapy, Comb | 2002 |
Levofloxacin-induced granulomatous interstitial nephritis.
Topics: Female; Granuloma; Humans; Levofloxacin; Middle Aged; Nephritis, Interstitial; Ofloxacin; Urinary Tr | 2003 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprof | 2002 |
[Comparative in vitro bacteriostatic and bactericidal activity of levofloxacin and ciprofloxacin against urinary tract pathogens determined by MIC, MBC, Time-Kill curves and bactericidal index analysis].
Topics: Anti-Infective Agents; Ciprofloxacin; Gram-Negative Bacteria; Humans; Levofloxacin; Microbial Sensit | 2002 |
Pyocystis in patients on chronic dialysis. A potentially misdiagnosed syndrome.
Topics: Aged; Anti-Infective Agents; Diagnostic Errors; Diverticulitis; Female; Humans; Kidney Failure, Chro | 2002 |
[Cefepime (maxipime) in the treatment of severe urinary tract infection].
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Ciprofloxacin; D | 2003 |
Longer than recommended empiric antibiotic treatment of urinary tract infection in women: an avoidable waste of money.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Drug Administration Schedule; Drug Costs; D | 2004 |
Physician adherence to recommendations for duration of empiric antibiotic treatment for uncomplicated urinary tract infection in women: a national drug utilization analysis.
Topics: Adolescent; Adult; Aged; Drug Utilization; Female; Humans; Middle Aged; Nitrofurantoin; Ofloxacin; T | 2004 |
Urinary tract infection caused by Aerococcus viridans, a case report.
Topics: Aged; Aged, 80 and over; Bacteremia; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Male; | 2004 |
[Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community].
Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Community-Acquired Infections; Escherichia col | 2005 |
Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli | 2005 |
[Uroinfections and the possibilities of therapy with levofloxacin].
Topics: Anti-Infective Agents, Urinary; Drug Administration Schedule; Genital Diseases, Male; Humans; Levofl | 2004 |
[Results of the study on antibiotic resistance emergence among pathogens of community-acquired urinary tract infections in Moscow. Phase I].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Bacterial Infections; Ce | 2005 |
In vitro activity of lomefloxacin, a new difluorinated quinolone, against urinary bacterial isolates: comparison with enoxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacteria; Enoxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Of | 1989 |
In vitro and clinical evaluation of ofloxacin in urinary tract infection and enteric fever.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Humans; Microbial Sensitivity Tes | 1989 |
Ofloxacin in the treatment of genito-urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Female Urogenital Disea | 1989 |
Experience with ofloxacin for short and long-term treatment of urinary tract infections in renal transplant recipients.
Topics: Follow-Up Studies; Humans; Kidney Transplantation; Ofloxacin; Postoperative Complications; Recurrenc | 1989 |
Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteri | 2005 |
A puzzling case of high serum creatinine in a healthy woman.
Topics: Adult; Anti-Bacterial Agents; Creatinine; Drug Administration Schedule; False Positive Reactions; Fe | 2006 |
Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Electrocardiography; F | 2006 |
Clinical efficacy and tolerability of levofloxacin in patients with liver disease: a prospective, non comparative, observational study.
Topics: Administration, Oral; Anti-Bacterial Agents; Chronic Disease; Drug Tolerance; Female; Humans; Levofl | 2006 |
A Rare but serious side effect of Levofloxacin: hypoglycemia in a geriatric patient.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Levofloxacin; Middle Aged; Ofloxacin; Pneum | 2006 |
Continuous versus intermittent levofloxacin treatment in complicated urinary tract infections caused by urinary obstruction temporarily relieved by foreign body insertion.
Topics: Anti-Infective Agents, Urinary; Biofilms; Drug Administration Schedule; Female; Foreign Bodies; Huma | 2006 |
Prevalence and natural history of colonization with fluoroquinolone-resistant gram-negative bacilli in community-dwelling people with spinal cord dysfunction.
Topics: Anti-Bacterial Agents; Carrier State; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; | 2006 |
Levofloxacin-induced interstitial nephritis and vasculitis in an elderly woman.
Topics: Acute Kidney Injury; Aged, 80 and over; Anti-Bacterial Agents; Fatal Outcome; Female; Humans; Levofl | 2006 |
In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Topics: Anti-Infective Agents, Urinary; Bacterial Adhesion; Ciprofloxacin; Dioxolanes; Drug Resistance, Bact | 2007 |
[In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dioxolanes; Drug Resistance, Multiple, Bacterial; Fluoroquinol | 2006 |
[A case of urinary tract infection caused by Flavimonas oryzihabitans].
Topics: Anti-Infective Agents, Urinary; Bacteriuria; Carbapenems; Drug Resistance, Multiple, Bacterial; Fema | 2007 |
[Drug-resistant bacteria isolated from pharyngeal swab cultures and urine in acutely or chronically febrile elderly nursing home inmates].
Topics: Acute Disease; Aged; Chronic Disease; Drug Resistance, Bacterial; Escherichia coli; Fever; Fluoroqui | 2007 |
Multidrug-induced erythema multiforme.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Ceftriaxone; Ci | 2007 |
Tissue reactions of suture materials (polyglactine 910, chromed catgut and polydioxanone) on rat bladder wall and their role in bladder stone formation.
Topics: Animals; Anti-Infective Agents, Urinary; Catgut; Cystitis; Female; Foreign-Body Reaction; Mucous Mem | 2008 |
Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis.
Topics: Aged; Anti-Bacterial Agents; Biopsy, Needle; Blood; Carbapenems; Cephalosporins; Drug Resistance, Ba | 2008 |
Demonstration of persistence of Salmonella typhimurium in an AIDS patient by molecular methods.
Topics: Adult; AIDS-Related Opportunistic Infections; Bacteriophage Typing; Bacteriuria; Diarrhea; DNA Trans | 1994 |
Lack of increase in resistance to quinolones in general practice isolates of Escherichia coli.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Clavulanic Acids; | 1994 |
North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
Topics: Bacteria; Bacterial Infections; Canada; Ciprofloxacin; Enterobacteriaceae; Female; Genitalia; Humans | 1994 |
Single dose of ofloxacin treatment in women with dysuria and frequency.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Drug Resistance, Micr | 1993 |
Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
Topics: Adult; Anti-Infective Agents; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infectio | 1993 |
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Lung Diseases | 1993 |
[Ecology of pathogenic bacteria in the infected urine].
Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; Drug Resistance, Microbial; Escherichia co | 1996 |
Therapeutic effects of cefozopran against experimental mixed urinary tract infection with Enterococcus faecalis and Pseudomonas aeruginosa in mice.
Topics: Ampicillin; Animals; Cefozopran; Ceftazidime; Cephalosporins; Cilastatin; Enterococcus faecalis; Fem | 1997 |
Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Asparagine; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; DNA, Bact | 1997 |
Neuropsychiatric complications following quinolone overdose in renal failure.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary; Confusion; Drug Over | 1999 |
The influence of ofloxacin (Tarivid) on the parasite-host inter-relationship in patients with chronic urinary tract infection.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Bacterial Adhesion; Colony Count, Microbial; Female; Hu | 1999 |
National guideline for the management of prostatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
Topics: Adrenergic alpha-Antagonists; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, U | 1999 |
Shiga toxin-producing Escherichia coli urinary tract infection associated with hemolytic-uremic syndrome in an adult and possible adverse effect of ofloxacin therapy.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Escherichia coli Infections; Escherichia coli O157; Fem | 2000 |
[Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Ba | 2000 |
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Gatifloxaci | 2000 |
Effect of Mao-bushi-saishin-to on infection of ofloxacin resistant bacteria and of unknown origin.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Inflammatory Agents; Bacterial Infections; Body | 2000 |
[Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
Topics: Acute Disease; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Bronchit | 2000 |
Seasonal variation in fluoroquinolone prescribing.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Utilization Review; England; Humans; Norfloxacin; Ofloxac | 1999 |
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.
Topics: Anti-Infective Agents, Urinary; Electrocardiography; Female; Humans; Levofloxacin; Middle Aged; Oflo | 2001 |
Activity of levofloxacin and ciprofloxacin against urinary pathogens.
Topics: Anti-Infective Agents; Bacterial Adhesion; Ciprofloxacin; Drug Resistance, Microbial; Escherichia co | 2001 |
The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans.
Topics: Adult; Aged; Anti-Infective Agents; Candida albicans; Ciprofloxacin; Digestive System; Female; Human | 2001 |
Patient-initiated treatment of recurrent urinary tract infection in women.
Topics: Adult; Anti-Infective Agents, Urinary; Female; Follow-Up Studies; Humans; Middle Aged; Ofloxacin; Pa | 2001 |
Acute fatal hepatitis related to levofloxacin.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary; Chemical and Drug In | 2001 |
Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate.
Topics: Aged; Anti-Infective Agents; Humans; Male; Middle Aged; Norfloxacin; Ofloxacin; Postoperative Compli | 2001 |
[Antibiotics in urinary tract infections. One quinolone for 3 days].
Topics: Anti-Infective Agents, Urinary; Clinical Trials as Topic; Drug Administration Schedule; Humans; Oflo | 2001 |
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Cipro | 2001 |
[Efficacy of a single-day administration of levofloxacin for the prevention of urinary tract infections after urogenital examinations and treatments for outpatients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents, Urinar | 2001 |
Effect of subminimal inhibitory concentrations of three fluoroquinolones on adherence of uropathogenic strains of Escherichia coli.
Topics: Anti-Infective Agents; Bacterial Adhesion; Cell Line; Ciprofloxacin; Escherichia coli; Escherichia c | 2002 |
[Profile and sensitivity to antibiotics of 2063 uropathogenic bacteria isolated in the center of Tunisia].
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Bacteria; Colistin; Escherichia coli; Female; | 2002 |
[Resistance to new quinolones among the enterobacteria].
Topics: Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Nalidixic Aci | 1992 |
[Clinical evaluation of oral ofloxacin in 3-day therapy for transurethral resection of the prostate].
Topics: Administration, Oral; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Ag | 1992 |
The dipstick test in the diagnosis of UTI and the effect of pretreatment catheter exchange in catheter-associated UTI.
Topics: Bacteriuria; Esterases; Evaluation Studies as Topic; Humans; Japan; Leukocyte Count; Levofloxacin; N | 1992 |
Ofloxacin-induced delirium.
Topics: Delirium; Female; Hospitalization; Humans; Middle Aged; Ofloxacin; Psychoses, Substance-Induced; Uri | 1992 |
[Ofloxacin: a new ally in the treatment of urinary infections and bacterial prostatitis].
Topics: Bacterial Infections; Humans; Male; Ofloxacin; Prostatitis; Urinary Tract Infections | 1992 |
[Clinical study of levofloxacin (DR-3355) on uro-genital infections--with special reference to usefulness for chronic prostatitis].
Topics: Adult; Aged; Chronic Disease; Drug Administration Schedule; Epididymitis; Escherichia coli; Humans; | 1992 |
Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.
Topics: Anti-Infective Agents; Bacteria; Drug Resistance, Microbial; Enterobacteriaceae; Haemophilus influen | 1992 |
In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dogs; Drug Evaluati | 1991 |
Ofloxacin during the second trimester of pregnancy.
Topics: Adult; Cartilage, Articular; Female; Fetus; Gestational Age; Humans; Infant, Newborn; Maternal-Fetal | 1991 |
[In vitro sensitivity of gram-negative bacteria isolated from urinary tract infections to various antibiotics].
Topics: Amikacin; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ceftazi | 1991 |
Effects of ofloxacin on cell-mediated immune response and lymphokine production.
Topics: Analysis of Variance; Humans; Immunity, Cellular; Interferon Type I; Interferon-gamma; Interleukin-2 | 1990 |
[Pefloxacin in the treatment of recurrent urinary tract infections].
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Ofloxacin; Pefloxacin; Recurrence; Urinary Tract Inf | 1990 |
[In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].
Topics: Aged; Anti-Infective Agents, Urinary; Bacteria; Cross Infection; Dose-Response Relationship, Drug; F | 1986 |
[An epidemiologic study of the antibiotic susceptibility of bacteria isolated from patients with urinary tract infections].
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Bacteria; Cefotaxime; Escherichia coli; Escheric | 1989 |
Effect of ofloxacin in the treatment of genitourinary tract infection with Ureaplasma urealyticum.
Topics: Adult; Humans; Male; Mycoplasmatales Infections; Ofloxacin; Ureaplasma; Urinary Tract Infections | 1989 |
Clinical role of the quinolones today and in the future.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Clinical Protocols; Forecasting; Humans; | 1989 |
In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Mice; Microbial | 1989 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquino | 1989 |
[Assessment of the genotoxic risk caused by the gyrase inhibitor ofloxacin using sister chromatid exchange rate analysis].
Topics: Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Ofloxacin; Oxazines; Sister Chr | 1988 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthy | 1987 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1986 |
[Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium; Corynebacterium Infections; Drug Resistance, | 1988 |
In vitro susceptibility of urinary pathogens to quinolones compared to other antimicrobial agents.
Topics: Anti-Bacterial Agents; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Norfloxacin; Ofloxac | 1987 |
[Clinical reevaluation of ofloxacin (OFLX) in urinary tract infections].
Topics: Adult; Aged; Aged, 80 and over; Drug Evaluation; Humans; Middle Aged; Ofloxacin; Oxazines; Urinary T | 1988 |
[Treatment of complicated urinary tract infections by ofloxacin].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; | 1988 |
[Therapy of complicated urinary tract infections using ofloxacin--a 2d generation antibacterial quinolone].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Female; Humans; Male; Middle Aged; O | 1988 |
[Personal experience with ofloxacin in patients with resistant urinary tract infections].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Drug Resistance, Microbial; Female; | 1988 |
[Clinical study of ofloxacin in complicated urinary tract infection].
Topics: Administration, Oral; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Ofloxacin; Urinary Tract I | 1988 |
Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Diabetes Mellitus, Experimental; Female; Fluoroquinol | 1988 |
In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Microbial Sensitivity Tests; Nalid | 1988 |
Serum and prostatic tissue concentrations of ofloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Half-Life; Humans; Male; Middle Aged; Ofloxacin; Post | 1988 |
Single low-dose ofloxacin for the treatment of uncomplicated urinary tract infection in young women.
Topics: Adolescent; Adult; Contraceptive Devices, Female; Contraceptives, Oral; Female; Humans; Middle Aged; | 1988 |
[The in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections].
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Enterobacteriaceae; Humans; Ofloxa | 1988 |
In vitro and clinical evaluation of ofloxacin in urinary tract infection and enteric fever.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; beta-Lactamases; Enterobacteriaceae; Half-Life; Humans; | 1988 |
[Ofloxacin (RU 43280). Clinical study].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Drug Therapy, Combination; Enterobacteriaceae Infect | 1987 |
[The role of ofloxacin (Tarivid) therapy in respiratory and urinary tract infections].
Topics: Acute Disease; Chronic Disease; Escherichia coli; Humans; Klebsiella; Ofloxacin; Proteus; Pseudomona | 1987 |
[Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results].
Topics: Adult; Aged; Aluminum Hydroxide; Anti-Infective Agents, Urinary; Bacteria; Bacterial Infections; Cre | 1986 |
Ofloxacin: clinical evaluation in urinary and respiratory infections.
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Male; Middle Aged; Ofloxacin; Oxazines; Pneumoni | 1986 |
Ofloxacin therapy of difficult-to-treat infections due to multiresistant organisms.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacteriuria; Drug Re | 1987 |
[Clinical study of ofloxacin (OFLX) on urinary tract infections].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Bacteria; | 1987 |
[Clinical evaluation of ofloxacin against complicated urinary tract infections].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Bacteria; Drug | 1987 |
Application of ofloxacin in gynaecology.
Topics: Anti-Bacterial Agents; Female; Genital Diseases, Female; Humans; Lactobacillus; Microbial Sensitivit | 1987 |
Bacteriological and clinical experiences with ofloxacin in urinary tract infections.
Topics: Anti-Bacterial Agents; Bacteria; Drug Resistance, Microbial; Humans; Ofloxacin; Urinary Tract Infect | 1987 |
Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cross Infection; Dose-Response Relationship, | 1986 |
[Ofloxacin (RU 43280): clinical evaluation in urinary and prostatic infections].
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Cystitis; Female; Humans; Male; Middle Age | 1986 |
The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Naph | 1985 |
[Anti-bacterial effect of ofloxacin--in vitro and in vivo results].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Enterobacteriaceae; Humans; Microbial Sensiti | 1985 |
[The study of urinary tract infection with a possible cause of fungi and evaluation of the efficacy of 5-FC].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Candida albicans; Candidiasis; Cyto | 1985 |